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I. INTRODUCTION 
A. The Early Development of the Mouse 
After fertilization, the zygote undergoes a series of cell divi­
sions that culminate in the implantation of the embryo into the uterine 
wall. Within 24 to 48 hours of fertilization, the zygote divides it­
self and gives rise to two biastomeres of approximately equal size 
(Rafferty, 1970). During this division, and the three subsequent ones, 
the embryos are named according to the cell stage (i.e., "4 cell" stage 
embryos or "8 cell" stage embryos). The next division brings a dramatic 
morphological alteration. The blastomeres "compact" to give a solid 
ball of cells, the morula, in which individual cells cannot be discerned 
by gross observation. Cavitation characterizes the next embryonic 
stage which generally occurs one day after the morula stage is reached. 
This is the early blastocyst stage. Here, the embryo consists of an 
outer layer of trophéetoderm cells which surround a blastocoelic cavity 
and a solid cluster of cells called the inner cell mass or ICM (Daniel, 
1978). 
Most mammalian embryos go through another stage called late 
blastocyst. However, at this stage, embryos can start to differ 
dramatically among mammalian species. While a mouse embryo is relatively 
small (100 (jan diameter) having only 250 cells at implantation (Rafferty, 
1970), a pig blastocyst could be one meter long with millions of cells. 
However, early development is so similar between mammalian species that 
easy and useful comparisons can be made. Due to its availability, 
the mouse is the species of choice in the study of early development. 
2 
Mice are relatively inexpensive and genetically inbred, recombinant, 
and congenic strains are available. 
There is very little information about how early development is 
controlled. Several approaches have been taken for the study of pre-
Implantation development. The first and simplest way to study 
development would be the observation of morphological changes during 
ontogeny. 
1. Morphology 
Tarkowski and Wroblewska (1967) showed that individual cells from 
"4 to 8" cell embryos are equivalent and totipotent. However, by 
the morula stage, the differentiation of blastomeres into trophoblast 
and inner cell mass depends in the first instance on their position 
occupied in the morula. That is, the "inside" and "outside" cells 
of the morula will be committed to different patterns of differentia­
tion (Hillman et al., 1972; Kelly, 1979). 
It is at the morula stage that most changes start to occur. The 
first change is compactation which starts at the 8-16 cell stage 
and leads to lack of definition of individual blastomeres. At this 
stage, the blastomeres appear to maximize contact with neighboring 
cells and very often assume irregular shapes. Here the blastomeres 
form tight junctions (Ducibella et al., 1975) and exhibit differences 
in cytoplasmic basophilia between cells, which may precede differentia­
tion (Calarco and Brown, 1969). 
The start of the blastocyst stage is marked by the formation of 
the blastocoel, a fluid filled cavity derived from the contents of the 
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cytoplasmic vesicles (Calarco and Brown, 1969). The expansion of the 
blastocoel, the formation of the trophoblast and the ICM are simultaneous 
and critical events in development. The trophoblast will develop into 
the placenta and other fetal membranes, while the ICM gives rise to the 
embryo proper and some of its extraembryonic structures (Rossant, 1977). 
Snow (1973) has suggested that determination does occur as early as * 
the 16 cell stage embryo. 
These experiments are by no means conclusive, since no other evi­
dence for early determination has been put forward. It is unclear when 
I CM and trophectoderm cells are committed to their respective patterns 
of differentiation. By producing hexaparental mice. Markert and Fetters 
(1978) showed that at least three ICM cells give rise to a fetus. Other 
studies have shown that ICM cells are not committed until primary ecto­
derm and endoderm are formed (Pederson et al., 1977). 
In contradiction to these studies, Modlinski (1981) has shown that 
ICM and trophoblast cells may be already committed at the early blasto­
cyst stage. The study shows that murine trophoblast and ICM nuclei are 
different from one another and can trigger different developmental 
patterns when transplanted into fertilized mouse eggs. These data sup­
port the hypothesis that determination is not a continuous process but 
rather occurs just prior to blastocyst formation, all cells being 
labile until chat time. 
All these studies suggest that commitment at the blastocyst stage 
is a two-way event, with both trophectoderm and ICM becoming committed 
at approximately the same time. Until the exact time of determination 
is known, it is difficult to speculate on the mechanisms involved. 
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Rossant (1977) suggests that determination may begin around the time of 
compactation. However, if determination occurs at a later stage, then 
compactation is a phenomenon of different implication. Rossant (1977) 
believes that it is unlikely that embryos have a built-in mechanism 
that at a given time responds to environment and commits the cells to 
differentiation. In summary, morphological studies describe "changes" 
during preimplantation development, but provide little insight into the 
genetic mechanisms responsible for these changes. 
2. Molecular events in preimplantation 
The second approach taken to the study of early development has 
been the observation of molecular events and gene activities in the 
young embryo. It is known that the newly fertilized mammalian egg 
actively synthesizes RNA (Warner, 1977). This has been demonstrated 
by autodiagraphy and by qualitative and quantitative analysis of the 
RNA produced (Schultz and Tucker, 1977). Nevertheless, the demonstration 
of synthetic activity by the embryonic genome is not really proof that 
the activity is essential for development. The problem is identifying 
specific RNA and protein products at each stage of development and 
then correlating their presence with a particular function in differentia­
tion. 
There is evidence that at the blastocyst stage there is mRNA. 
synthesis and there is a sufficient supply of ribosomes and tRSA to 
allow for the production of differentiated gene products (Sherman, 
1979). Also, RNA polymerase enzyme activity has been shown in pre­
implantation mouse embryo homogenates (Warner and Versteegh, 1974; 
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Warner, 1977). Moreover, relative amounts of the different enzyme 
forms were shown to change between the "8 cell" and the blastocyst stage 
which may indicate their involvement in differentiation (Warner, 1977). 
RNA synthesis has been shown in "2 cell" stage embryos (Ellem and Gwatkin, 
1968), in "8 cell" stage embryos (Piko, 1970) and in morula and early 
blastocyst stages (Daentl and Epstein, 1973; Epstein and Daentl, 1971). 
There appears to be no net increase in protein content in the 
cleavage stage embryo (Brinster, 1967). Moreover, in the mouse, there 
seems to be a slight decrease in total protein content from fertiliza­
tion through cleavage and even in the blastocyst stage (Schiffner and 
Spielman, 1976). It is difficult to reconcile this observation with the 
fact that differentiation is occurring. It must be deduced that quite 
a bit of protein breakdown and resynthesis must occur during this 
time. Most of the interest in protein synthesis lies in the study of 
surface proteins, since these proteins can be used as markers of dif­
ferentiation. 
3. The surface of preimplantation embryos 
a. Embryos as antigens The third approach that has been 
taken in the study of early mouse development is the study of surface 
proteins. Research workers have attempted to relate their knowledge 
of the cell surface to its. possible role during development. Cell 
surface components could play the following roles during preimplanta­
tion (Johnson and Calarco, 1980): 
1. Recognition (sperm-egg, ICM-trophéetoderm, trophectoderm-
uterine cells); 
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2. Adhesion; 
3. Motility, particularly in the development and invasiveness 
by trophectoderm cells; 
4. Communication; 
5. Protection of the fetus from maternal immunological attack; and 
6. Receptors for the induction of intracellular changes. 
The most common and most widely used approach to the study of the 
cell surface of embryos is the use of specific antisera. Antibodies 
have been produced to embryos at all stages of preimplantation from 
spermatozoa and unfertilized eggs to the late blastocyst stage. Heath 
(1978) produced a rabbit antiserum that reacted with germ cells of 
fetal mice. This antibody reacted also with carcinoma cells of four 
different teratocarcinoma cell lines. The antiserum also reacted with 
germ cells of adult mice but not with nongerminal tissue. This anti­
body could be detecting a surface product involved in differentiation. 
Xenogeneic antiserum has been raised to unfertilized mouse eggs 
(Moskalewski and Koprowski, 1972). This antiserum, which was raised in 
guinea pigs, also reacted with preimplantation stage embryos. It must 
be pointed out that the antibody was raised against pronase treated 
eggs. Thus, these observations have to be analyzed in light of the 
fact that the enzyme could affect the surface of the embryos. Pronase 
has been shown to profoundly alter cell surface properties (walach, 
1972) and the antigenicity of mouse eggs and preimplantation embryos 
in particular (Wiley and Calarco, 1975). 
In 1975, Wiley and Calarco developed two rabbit antisera, one 
against mouse blastocysts and a second against mouse placentae. The 
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antisera were produced by injecting male rabbits with blastocysts freed 
of the zonae mechanically by mouth pipet. After being absorbed with 
adult mouse tissues, the antisera reacted weakly (immunofluorescence) 
with unfertilized mouse eggs and zygotes. 
The antisera were not reactive against teratocarcinoma cells. The 
second rabbit antiserum prepared by immunization with mouse blastocysts 
showed a similar pattern of reactivity with preimplantation embryos 
(Johnson and Calarco, 1980). This last antiserum does not cross react 
with adult mouse tissues, nor does it react with a number of terato­
carcinoma cell lines. Glass and Hansen (1974) described three antisera 
raised in rabbits against mouse cumulus oocyte masses, morulas and 
blastocysts. Embryos with intact zonae were used. Anti-cumulus oocyte 
mass and anti-blastocyst sera, even after absorption with mouse cells, 
caused the immediate death of cultivated mouse embryos. This antiserum, 
however, had a high activity against the zona pellucida, a problem that 
is prevalent in the use of xenogeneic antisera. The zona has been 
shown to be a strong immunogen and activity against it can be high 
after xenogeneic immunization (Solter and Knowles, 1979). In the search 
of finding a stage specific embryonic antigen (SSEA), which would be 
an excellent probe for development, some investigators have treated 
embryos with antisera raised against teratocarcinoma cell lines. 
b. Teratoma antigens Teratomas contain a wide variety of 
cell types corresponding to derivatives of the three embryonic germ 
layers. When transplantable, they are called teratocarcinomas and 
contain, in addition, embryonic-like cells called embryonal carcinoma 
cells (EC) (Pierce, 1967). The EC possess two important properties 
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that make them ideal for comparative studies with embryos : 1. They 
have many characteristics in common with early embryonic cells and 
can differentiate into derivatives of the three germ layers (Jacob, 
1979); and 2. they are easily cultured in vitro. Cells derived from 
teratocarcinomas can also be obtained from solid tumors and embryoid 
bodies present in ascites. By their shape, these bodies recall pre-
implantation stages of mouse embryos (Jacob, 1979). 
Â number of teratocarcinoma cell lines have been established in 
culture in various laboratories, which have used them as antigens for 
the study of the embryonic surface. Edidin and Goodin (1975) developed 
a rabbit antiserum against embryoid bodies of a multipotential ascites 
subline (402x). The serum was reported to be cytotoxic for pronase-
treated unfertilized eggs and to localize on the ICM of the mouse blasto­
cyst. The authors suggested that the antigens detected could be pre­
cursors of H-2 antigens. 
One important characteristic of embryonal carcinoma cells is that 
they apparently do not express H-2 antigens. These cells do not 
react with specific allogenic anti-H-2 sera (Artzt and Jacob, 1974). 
EC cell line F9, if injected in 129 strain male mice, produces 
cytotoxic antibody (Artzt et al., 1973). This syngeneic antiserum de­
tects what is widely called the F9 antigen (Gachelin et al., 1977; Jacob, 
1977, 1978). F9 antigen is present on spermatozoa (Artzt et al., 
1974) but not on any of the somatic cells tested (Jacob, 1979). In the 
embryo, the F9 antigen can be detected a few hours after fertilization, 
and it is present up to the blastocyst stage in both trophéetoderm 
and ICM (Jacob, 1979). Culture of mouse embryos in the presence 
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of syngeneic anti-F9 serum inhibits compactation (Kemler et al., 1977). 
It is claimed that the F9 antigen may be related to the T/t ccanplex 
(Artzt et al., 1974). Two lines of evidence support this hypothesis: 
1. Absorption experiments with sperm indicate that sperm 
from heterozygotes for one particular "t" haplotype contain half the 
amount of F9 antigen than spermatozoa of the wild type (Artzt et al., 
1974). 
2. The segregation of F9 antigen in different crosses suggests 
that its expression is controlled by a gene closely linked or within 
the T/t complex (Kemler et al., 1977). Due to the proven involvement 
of the T/t complex in embryogenesis (Artzt and Bennett, 1975), the 
mentioned data support the idea that F9 is the closest to a SSEA. 
Other teratocarcinoma cell lines have been used to produce specific 
antiserum. For example, syngeneic antisera were produced against 
embryoid bodies of the ascites form of 0TT6050 teratoma (Dewey et al., 
1977). This antiserum detected cell surface antigens on mouse embryos 
from the "2 cell" stage to blastocyst. Also, syngeneic antibodies have 
been produced to cell line PCC4. These antibodies reacted with adult 
sperm but not with preimplantation embryos (Gachelin et al., 1977). 
c. H-2 antigens and the embryo surface The last set of sur­
face antigens that will be reviewed are the major histocompatibility 
antigens (MHC). They are especially important gince they are directly 
related to our study. The MHC (H-2) of the mouse is located in the 
middle portion of chromosome 17 and is between 0.3 and 1.5 centimorgans 
long (Klein, 1979). Traditionally, the H-2 complex is viewed as a 
chromosomal segment containing a tightly linked series of genes which 
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control a variety of traits of immunological significance (Shreffler 
and David, 1975). Each locus in this chromosomal segment is considered 
part of the MHC. The complex is divided into four main regions, K, 1, 
S and D, and the I region is further divided into five subregions, 
I-A, I-B, I-J, I-E and I-C (Klein, 1979). The G region has been re­
cently placed between the S and D regions (Klein, 1979). The K and D 
regions, which are located on opposite ends of the H-2 complex (K 
closest to the centromere), code for antigens capable of stimulating 
alloantibody production and graft rejections (Vitteta and Capra, 
1978). They are serologically complex antigenically and extremely 
polymorphic (Klein, 1979). These antigens are considered Class I 
antigens (Klein et al., 1978). The Class II antigens are the I-A 
antigens which are coded by the I region of the H-2 complex (Shreffler 
and David, 1975). The I-A gene products were originally detected sero­
logically with antibodies. They were later shown to be responsible 
for the activation of lymphocytes in mixed lymphocyte cultures (Klein, 
1979). Another set of Class II antigens are the Ir gene-controlled 
products, which regulate the immune response as measured by antibody 
production (Shreffler and David, 1975), delayed type hypersensitivity 
or proliferation of thymus derived (T) lymphocytes in vitro (Benacerraf 
and Germain, 1978). The relation between la and Ir genes is still 
confusing. Both sets of genes map in the same position and all attempts 
to find Ir gene products different from la molecules have been unsuc­
cessful. Therefore, it is now generally accepted that the Ir gene 
products are the la antigens (McDevitt, 1981). 
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Class III antigens are coded by the S and G regions. These antigens 
are ser^nn proteins and erythrocyte surface antigens. One of the most 
difficult things to understand is the extensive polymorphism of the 
H-2 complex. Some 60 or more traits have been claimed to be controlled 
by the complex (Klein, 1978). The question raised is whether there is 
one locus for each of the 60 traits or whether single loci control 
groups of traits in a pleiotropic fashion. 
Recently, a simplified view of the H-2 complex has been put for­
ward (Klein et al., 1981). In this model, the H-2 complex is divided 
into only two classes of loci. Class II loci are composed of A^, A^, 
E and Eg molecules, and the class I loci are the K and D molecules. 
a P 
Class III molecules are not considered to be a functional part of the 
complex. Klein et al. (1981) have also disposed of the region-subregion 
terminology and retain only the term locus. They also eliminate the 
I-B and I-C subregions. According to this model, only a small number 
of protein products are responsible for the large number of traits 
which map to the complex. 
Regardless of the correct model for the H-2 complex, the localiza­
tion of H-2 antigens on mouse embryos has proven difficult. H-2 
antigens have been detected on sperm and unfertilized ova (Edidin, 1972; 
Johnson and Edidin, 1972). Heyner and Hunziker (1979) found evidence 
of H-2 antigens in oocytes and "1 cell" zygotes but not in "2 
cell" stage embryos. Their failure to detect H-2 antigens in cleavage 
embryos joins a long series of unsuccessful studies trying to find 
H-2 antigens on early embryos (Billington et al., 1977; Heyner, 1973; 
Muggleton-Harris and Johnson, 1976; Palm et al., 1971). There 
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is good evidence that H-2 antigens are present in 7-9 day mouse embryos 
(Pathy and Edidin, 1973); it is in the earlier stages that they have 
been difficult to find. Searle et al. (1976), using an electron 
microscope immunoperoxidase technique, demonstrated the presence of H-2 
antigens on trophectoderm of blastocysts. Also, Webb et al. (1977) 
showed the presence of H-2 products on ICM cells. Finally, in studies 
from our laboratories, using a highly sensitive cytotoxicity assay 
(Cozad and Warner, 1981), it has been shown that H-2 antigens are present 
on blastocysts. Krco and Goldberg (1977) showed the presence of H-2 
antigens in "8 cell" stage embryos. This has recently been confirmed 
in our laboratory^. Based on all these studies, it can be safely con­
cluded that H-2 antigens are expressed in most stages of preimplantation. 
The failure to prove their presence at earlier stages ("2 cell"-"4 cell") 
probably represents a lack of sensitivity of the techniques used. 
4. The timinp; of cleavage in early embryos 
The last approach taken to the study of development and the one 
that this work addresses is the study of timing events in preimplanta­
tion. Timing in development has been the subject of just a few studies 
in the past (Soil, 1979). Most of the studies are based on the observa­
tion that in mammalian embryos, cell division is almost immediately 
asynchronous after fertilization. Thus, in the mouse at a certain time 
after fertilization, some embryos will contain fewer cells than others 
(Rafferty, 1970). This observation has been confirmed in rats, where 
embryos have also been shown to be asynchronous in their cell division 
M. Cozad, Biochemistry and Biophysics Department, Iowa State 
University. 
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(Giavini and Prati, 1978). Also, Streffer et al- (1980) showed that 
synchronization in the mouse (strain not specified) is lost early in 
development (48 hours) and is more marked ig vivo than vitro. 
Some years ago. Gates et al. (1961) and Whitten and Dagg (1962) 
observed differences in the development of inbred mouse strains. Ac­
cording to their observations, blastocysts of BALB/c mice had, on the 
average, fewer cells per embryo than embryos from strain 129. Several 
years later, Titenko (1977) observed that CBA embryos have fewer cells 
at a given time than either BALB/c or C57BL/6 embryos. McLaren and 
Bowman (1973) showed that C3H embryos have fewer cells per embryo, at 
a given time, than the inbred strains C57BL, J and RIII. Based on 
their observations, they suggested that genetic factors influence 
the timing of early development. In other studies, Niwa et al. (1980) 
showed that there are distinct differences between strains of mice in 
the time of first cleavage. They showed that in spite of being 
fertilized at similar times, the C3H mice showed a lower percentage 
of "2 cell" embryos than the other three strains 20 hours after 
insemination. From the above studies, it is observed that both CBA and 
C3H are "slow" developing strains; both strains have the same H-2 
Icn Ic haplotype (H-2 )• Thus, it is reasonable to hypothesize that the H-2 
haplotype is associated with slow development. Genes linked to the MHC 
of the rat have been shown to affect development (Kanz et al., 1980). 
The growth and reproduction complex (GRC) of the rat, which is a group 
of genes closely linked to the MHC (Gill and Kunz, 1979), influences 
body size and fertility. Also, Melnick et al. (1981) have shown that 
genes at or near the H-2 complex are associated with both fetal loss 
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and fetal weight. 
In a preliminary study done in our laboratory, Verbanac and Warner 
(1981) showed that the H-2 complex may play a role in early embryonic 
development. Slow development is associated with the H-2 haplotype. 
The gene(s) associated with the H-2 complex are named Fed standing for 
preimplantation embryo development. In this dissertation, experiments 
will be described to analyze Fed gene expression. These studies will 
include the analysis of the range of Ped gene alleles, the description 
of the earliest time in development at which the Ped gene is expressed, 
studies on F^, and backcross embryos, and a search for the putative 
Fed gene product, the H-2 antigens, on the preimplantation mouse embryo 
cell surface. 
B. Monoclonal Antibodies 
1. Plasmacytomas 
Plasmacytomas or multiple myelomas are malignant neoplasms of plasma 
cells usually arising in bone marrow and are manifested by the 
presence of large amounts of circulating homogeneous immunoglobulins 
(Potter, 1972). Every plasmacytoma cell of independent origin 
is restricted to producing a single species of immunoglobulin, i.e., 
immunoglobulins of identical specificity (Potter, 1972). In 1962, 
Potter and Boyce were experimentally able to produce plasmacytomas 
in BALB/c mice by using mineral oil. The large amount of immuno­
globulin produced by this tumor was an unlimited source of homo­
geneous mouse immunoglobulins and the key in the chemical analysis 
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of these molecules (Potter and Lieberman, 1967). Plasmacytomas differ 
from lymphomas in cell morphology and in that lymphomas fail to cause 
paraproteinemia (anomalous amounts of circulating immunoglobulins) in the 
host animal (Horibata and Harris, 1970). Not only have plasmacytomas 
been useful in the study of immunoglobulins, but they have also pro­
vided an excellent somatic-cell genetic system (Margulies et al., 
1977). 
Although Horibata and Harris (1970) were able to grow plasmacytomas 
in vitro, it was disappointing to find out that they were not a good 
source of antibodies specific to known antigens. Thus, of thousands 
of mouse myeloma tumors induced, only a few produce immunoglobulins 
that react with known antigens (Potter, 1978). Trying to overcome these 
difficulties, investigators have transformed heterogeneous populations 
of sensitized lymphocytes with the use of viruses. In 1971, Baumal 
et al. transformed human sensitized peripheral blood cells with Epstein-
Barr (EB) virus. However, none of the cell lines produced antibody 
directed to the stimulating agent. One of the few limited successes 
was achieved by Strosberg et al. (1974). Using SV40 virus, they trans­
formed rabbit lymphocytes that produced antibody to pneumococcal type 
III polysaccharides. 
After plasmacytomas were grown iji vitro. Cotton and Milstein (1973) 
produced hybrids between mouse and rat myeloma cells. They observed 
that the hybrids continued to produce mouse heavy and light chains. 
In 1974, Schwaber and Cohen fused human peripheral blood lymphocytes 
with mouse myeloma cells. Gel electrophoresis analysis showed that 
the hybrids were producing both types of immunoglobulins, human and 
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mouse. On the other hand, in England, Kohler and Milstein (1975) 
decided to fuse a normal plasma cell with a plasmocytoma cell line 
called P3-X63Ag.8. This cell line was isolated from the original P3 
cell line isolated by Horibata and Harris in 1970. The cells are re­
sistant to 8-azaguanine and do not grow in selective medium (e.g., 
HAT medium). The normal cells used for the fusion were obtained from 
the spleen of a BALB/c mouse previously immunized with sheep red blood 
cells (sRBC). They discovered that the hybrids were producing both 
the myeloma protein and the anti-sRBC antibody. In this way, the normal 
B-cell became immortal through hybridization with a neoplastic cell. 
The fused cell was called a hybridoma. Several cell lines have been 
isolated that can be used for the production of hybridomas. Table 1 
is a summary of characteristics of cell lines used by most of the in­
vestigators in this field. 
When a clone of fused cells has been established, by definition, 
all of the antibody it secretes is genetically derived from a single 
cell (Milstein, 1981). It was clear from the beginning that the 
presence of hybrids was higher than expected from simply a random fusion 
of normal cells with tumor cells (Milstein, 1981). Apparently, with 
immortalization, there is enrichment of T or B cells which have been 
stimulated by antigen and have undergone blastogenesis. Thus, actively 
dividing cells are enriched by antigen stimulation and will preferentially 
fuse with the tumor cells (Melchers et al., 1978). One of the problems 
encountered with hybridomas is their lack of stability due to chromo­
somal loss (Milstein, 1981). Hybridomas can lose malignancy or immuno­
globulin production. When this happens, the loss is not random; heavy 
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Table 1. Summary of cell lines used for hybridoma production (Melchers 
et al., 1978) 
Cell line 
complete name Short name Strain Characteristics 
P3X63Ag-8 X63 BALB/c Plasmacytoma (y, k) 
P3-NSl-l-Ag4-l NS-1 BALB/c Plasmacytoma (k, nonsec) 
MPC11-X45-GTG X45 BALB/c Plasmacytoma (y^b, k) 
Sp2/0-Ag/4 Sp2 BALB/c Hybridoma (nonsec) 
X63-Ag8.653 — BALB/c Plasmacytoma (nonsec) 
BW5147 BW AKR Thymic lymphosarcomas^ 
EL-4 EL-4 C57BL Thymic lymphosarcomas 
^Thymic lymphosarcomas or thymomas are malignant tumors derived 
from the lymphoid elements of the thymus. 
chains are usually lost first and then one of the light chains is 
lost (Kohler, 1980). 
2. Interspecies and intraspecies hybridomas 
Several kinds of interspecies hybridomas have been produced. One 
example is rat-mouse hybridomas (Galfre et al., 1977; McKearn et al., 
1980), Using this type of hybridoma, McKearn et al. (1980) produced mono­
clonal antibodies against the MH.C of the rat. from these and other studies 
(Welb et al., 1979), it has been shown that rat-mouse hybridomas are 
more stable than mouse-mouse hybridomas. Also, rat-mouse hybridomas 
are useful because both cells carry different karyotypes and studies 
on gene regulation are facilitated. Furthermore, over 90% of the rat-
mouse hybridomas produce rat kappa light chains (McKenn et al., 1980) 
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which have a different allotype from the mouse (BALB/c) light chains 
providing an excellent marker for regulation studies. However, produc­
tion of mouse-mouse hybridomas has been reported by dozens of labora­
tories and apparently have the widest application (see below). 
Another potentially important type of interspecies fusion is the 
rabbit-mouse hybridoma. In 1980, Yarmush was successful in producing 
mouse-rabbit hybridomas. These could be an important source of specific 
antibodies against pathogenic microorganisms like paT1idinn (causal 
agent of syphilis), since the rabbit is the only good experimental 
model for syphilis (Bishop and Miller, 1976). The last of the important 
interspecies hybridomas are the mouse-human hybridomas. A good example 
of their application is the study published by Schwaber and Rosen (1978). 
B lymphocytes from an agammaglobulinemic patient were fused with mouse 
myeloma cells. These hybridomas produced both murine and human immuno­
globulins. This demonstrates the presence of structural genes coding 
for immunoglobulins in the cells of this patient. 
An important type of hybridoma is the human-human hybridoma (Olssen 
and Kaplan, 1980). They developed an 8-azaguanine resistant human myeloma 
and fused it with lymphocytes of patients with Hodgkin's disease that were 
previously sensitized with 2,4 dinitrochlorobenzene. They obtained cul­
tures producing specific human antibody to the chemical antigen. The 
potential of these human-human hybridomas in therapy and clinical diagnosis 
could be endless. 
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3. T cell hybridomas 
If the same population of spleen cells which contains similar 
numbers of B and T cells is fused with a myeloma or a T cell 
lymphosarcoma, the results are quite different (Milstein, 1981). When 
the fusion parent is the myeloma, the growing hybrids express the 
antibody-secreting phenotype of the parental spleen cell but do not seem 
to express the markers characteristic of T cells. On the other hand, 
when the fusion parent is a T cell lymphosarcona, the growing hybrids 
preferentially express the T cell characteristics. Thus, thymic 
lymphosarcomas were developed to produce T cell hybridomas. 
T cell hybridomas have been used to study suppressor cells and sup­
pressor factors. Supernatant fluids of T cell hybridomas can suppress 
expression of delayed type hypersensitivity (DTH) (Hewitt and Liene, 
1979) to sRBC stimulation. T cell hybridomas developed by Taussig et al. 
(1979) produced suppressor factors that reduced primary and secondary 
responses to sRBC. Accessory cells (e.g., macrophages) have been fused 
with multiple myeloma cells (Sethi et al., 1981). Two continuously 
multiplying hybrid cell lines were established which showed macrophage-
like activity and retained the macrophage-derived Fc receptor activity. 
These are useful studies of the role of macrophages in malignancy. 
4. Applications of monoclonal antibodies 
There are potentially limitless applications for monoclonal anti­
bodies. The following are just a few examples of these. 
Hybridomas have been used to study autoimmune diseases (Andrzejewsky 
et al., 1980; Tron et al., 1980). In these studies, homogeneous anti-
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DNA monoclonal antibodies were produced using mice showing Lupus-like auto­
immune disease. These studies could be useful for a better understanding 
of autoimmunity. Monoclonal antibodies have great potential as therapeutic 
agents. They can be effective against transplanted mouse leukemia (Bern­
stein et al., 1980) or even against parasitic diseases like malaria 
(Yoshida et al., 1980). Hybridomas can be powerful tools in purification 
processes. Using immunoabsorbent columns, Secher and Burke (1980) purified 
interferon 5000-fold in only one step without any loss of activity. 
The three areas in which monoclonal antibodies have already 
found wider clinical application are oncology, hematology and im­
munology. Specific monoclonal antibodies have been raised against 
several carcinoembryonic cell lines (Acolla et al., 1980) and also 
against neuroblastomas (Kennet and Gilbert, 1979). These antibodies 
were very specific and showed no cross reactivity with normal cells or 
other tumors. Monoclonals have been produced to T cell subpopulations 
and can be used to mark or separate T cell subpopulations (Welb et al., 
1979; Ziegler, 1980). Monoclonals have also been produced against 
human group A erythrocytes (Barnstable et al., 1978) with the goal of 
replacing conventional antisera, vAiich is expensive to produce. 
Monoclonals have also been raised to HLA antigens (Barnstable et al., 
1978) and (Ziegler, 1980). In the case of mice, 
monoclonals have been produced to H-2 and la antigens (Lemke et al., 
1978; Ozato, 1980). The antigenic specificities detected by these 
hybridomas were similar to those listed in H-2 charts, such as 
those of Danant (1979). This last class of monoclonals are of 
importance to our project because of their high specificity, we 
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decided to use this approach to show the presence of H-2 antigens on 
embryos. This is important because our working hypothesis is that the 
Ped gene(s) products are H-2 antigens. 
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II. MATERIALS AND lŒTHODS 
A. Mice 
The following inbred and congenic mouse strains were obtained 
from the Jackson Laboratory, Bar Harbor, ME: C57BL/10Sn, C57BR/cdj, 
CBA, C3H/HeJ, BALB/c, A/J, SJL, DBA/1, DBA/2, C57BL/6, BIO.BR, 
B10.D2, BIO.A, BIO.PL, and BIO.RIII. (The last two were purchased 
as mating pairs.) 
The BIO.S, BIO.Q and C3H.B10 mice were obtained from Dr. D. 
Shreffler, Washington University, St. Louis, MO; the BALB.K mice 
from B. Mishel, University of California, Berkeley, CA; and the BALB.B 
mice from Dr. R. Scibienski, University of California, Davis, CA. 
mice were bred in our laboratory. The CFl (outbred) 
mice were obtained from Charles River Breeding Laboratories, Wilmington, 
MA. The mice were housed in a day night cycled room with controlled 
temperature and food and water ^  libitum. The clock was never al­
tered during the year so that the room was light either from 6 a.m.-
8 p.m. standard time or from 7 a.m.-9 p.m. daylight savings time. 
B. Collection of Embryos 
Female mice 2-6 months old were super ovulated by injection with 
5 I.U. pregnant mare serum (PMS) (Organon Holland) followed 48 hours 
later by 10 I.U. human chorionic gonadotropin (hCG) (ICN, Nutritional 
Biochemicals, Cleveland, OH). All injections were either at 3 p.m. 
standard time or at 4 p.m. daylight savings time. Females were 
placed individually with a single male immediately after HCG in­
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jection, and checked for the presence of a vaginal plug the next 
morning. 
Plug positive females were sacrificed by cervical dislocation 
at various hours after hCG injection, depending on the desired 
developmental stage of the embryos. 
Embryos were collected at 24, 27, 30, 33, 36, 40, 47, 53, 56, 
and 65 hours post hCG from excised oviducts by flushing them with 
modified Iilhitten and Biggers (1968) culture medium using a blunt 
30 gauge needle. Embryos at 89 hours post hCG were collected by 
flushing the uterus. 
Embryos were collected in embryological watchglasses. The re­
covery and examination of embryos were performed under dissecting 
microscope (Bausch and Lomb, Rochester, NY). As soon as the embryos 
were collected, they were washed three times in Whitten and Biggers 
medium and placed in an atmosphere of 5% CO^ in air to maintain optimal 
pH. 
C. Determination of Cell Number 
During the first stages of development ("1 cell" to "5 cell" 
embryos), cell number was determined by direct microscopic inspection. 
For the later stages, a modified version of the Tarkowski (1966) 
procedure was used. In this method, individual embryos were washed 
free of culture medium and placed in 0.8% sodium citrate for 5-15 
minutes at room temperature. Next, the embryos were transferred to 
a clean slide and 0.02 ml drops of freshly prepared fixative (three 
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parts absolute ethanol:one part glacial acetic acid) were added. 
Usually, at least seven drops of fixative were required. Final 
scattering of nuclei was achieved by blowing on the embryos during 
air drying. 
The preparations were stored in Giemsa (GIBCO, Grand Island, 
NY) overnight and washed gently with distilled water. The nuclei 
were counted using a Zeiss phase contrast microscope (equipped with an 
integral illuminator) at 400x magnifications (Zeiss, New York, NY). 
D. Determination of Superovulation Time 
Female mice were injected with hormones as previously described 
but they were not mated. The ampullary portion of the oviduct was 
teased with fine forceps and the clutch of recently ovulated eggs was 
removed. The oviducts were then flushed with a solution containing 
300 units/ml hyaluronidase (1500 units/mg, Sigma, St. Louis, MO) in 
Whitten and Biggers medium to remove cumulus cells. 
E. Production of Monoclonal Antibodies 
1. Cells 
The NS-1 cells were obtained from Dr. Nancy Ruddle, Yale University, 
New Haven, CT. The Sp-2/0 cells were a gift from Dr. J. Davie, Washington 
University, St. Louis, MO. The 11-4.1 hybridomas were obtained from 
the Salk Institute, LaJolla, CA. 
The NS-1 cells, NS-1 hybridomas and 11-4.1 cells were grown in 
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sterile medium which consisted of low glucose (1000 mg/ml) Dulbecco's 
Modified Eagles Medium (D-MEM) (GIBCO, Grand Island, NY) supplemented 
with 10% fetal bovine serum (heat inactivated) (GIBCO) (or 10% 
gamma globulin free newborn bovine serum), 1% of antibotic/antimycotic 
solution (GIBCO) (Penicillin 10,000 units/ml, streptomycin 10,000 
ug/ml and fungizone 25 jAg/ml) and 0.5% garamycin (10 mg/ml, Schering 
Corporation, Kenilworth, NJ). 
2 Cells were grown in 25 cm tissue culture flasks (Corning, 
Fisher Scientific, St. Louis, MO) in humidified incubators in an 
atmosphere of 5% CC^, 95% air and a temperature of 37°C. 
The Sp-2/0 cells and Sp-2/0 hybridomas were grown in high glucose 
(4500 mg/ml) D-MEM (GIBCO) with 10% gamma globulin free horse serum 
(GIBCO), 5% calf serum (GIBCO) and the same concentration of anti­
biotics as already described. 
Cells were transferred twice a week by placing from 1 to 1.5 x 
5 2 10 cells/ml into 10 ml of fresh medium in 25 cm tissue culture flasks 
which were laid horizontally in the incubator with the caps loose. 
Viability counts were done routinely. The NS-1 cells were treated 
every 3-4 months with 8-azaguanine (Sigma) (2 lig/ml) to eliminate the 
presence of mutants and maintain susceptibility to aminopterin. 
The Sp-2/0 cells were treated at 3- to 4-week intervals. 
A stock solution of 8-azaguanine was prepared by dissolving 
10 mg of the drug in 10 ml of Hanks balanced salt solution. The drug 
was dissolved by increasing the pH to 10 using a IM NaOH solution. 
Next, the solution was neutralized to the original pH using a IM 
solution of HCl. The solution was filter-sterilized and divided into 
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1 ml aliquots. Before treating the cells, 1 ml of the stock 
solution was added to 500 ml of complete medium. 
2. Cell freezing and storage 
Freezing medium consisted of complete medium, plus an extra 
10% of serum (making a final concentration of 20% serum) and 10% 
dimethyl sulphoxide (Fischer). Medium for freezing was prepared 
fresh every week. 
Cells were centrifuged at room temperature at 200 x g for 
10 minutes and resuspended in freezing medium at a concentration of 
2-5 X 10^ cells/ml. Cells were aliquoted into one ml quantities in 
special polyestarane vials (Provials, Cooke, Alexandria, VA or 
Inter-Med vials. Nunc, Denmark). 
At the beginning of this project, the freezing of the cells was 
conducted with a Linde 4-2 Biological Freezing System (Union Carbide, 
NY) composed of a BF-6 controller, BA-2 freezing chamber, liquid 
nitrogen tank (22 psig) and a Bristol Dynamaster Recorder, Model 
PH560-51 (Waterbury, CT), with an adjusted chart speed of one inch per 
minute. The recorder was calibrated by placing the thermocouple 
probe into beakers containing distilled water at 25°C, 10°C, and 5°C, 
respectively. The cooling rate (degrees per minute) was calculated 
by dividing the temperature change by the chart speed. The control 
vial was connected to the thermocouple and inserted into the chamber. 
The controller was adjusted to a freezing rate of 1°C per minute. 
When the samples were approximately 4°C above freezing point (-IS^C), 
liquid nitrogen was allowed to flow continuously into the chamber 
26 
for 30 seconds eliminating random freezing of samples. The freezing 
was continued to -30°C and then changed to 10°C per minute to -70°C. 
Vials were then transferred to the liquid nitrogen container (LR-30, 
Union Carbide, NY). 
Later on in this project, a more economical, but equally effective, 
way to freeze cells was used. The apparatus used was a BF-5 
biological freezer (Union Carbide) which cools the cells using the 
cold gas evolved from the liquid nitrogen container. The freezer 
was adjusted to a freezing rate of l-2°C/minute and left for 45 
minutes to an hour in the tank, after which the vials were deposited 
in the storing tank. 
Cells were stored in a LR-30 liquid nitrogen container (Union 
Carbide) for years without losing more than 30% viability. Recovery 
of cells from the liquid nitrogen was achieved by quickly thawing 
the samples and diluting them slowly into 10 ml of fresh medium in 
a tissue culture flask. The flask was placed in the incubator over­
night. After 48 hours, a viability count was done and cells were 
transferred as usual. 
3. Immunization of mice 
All immunizations were done using only congenic mice. In this 
way, antibodies were directed exclusively to the H-2 coded antigens. 
For the production of anti-H-2^ antibodies, C57BL/10Sn mice were 
injected with BIO.BR splenocytes. Reciprocal injections were done 
to produce anti-H-2^ antibodies. 
Congenic mice with the BALB/c background were also used to 
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facilitate the production of tumors since BALB/c mice were the original 
sources of NS-1 cells. 
For the production of anti-H-2^ antibodies, BALB/c mice were in­
jected with BALB.K splenocytes and for the production of anti-H-2^ 
antibodies, BALB/c mice were injected with BALB.B cells. 
Immunization against whole spleen cells was done according to the 
method of Batchelor (1973). Single cell suspensions of the appropriate 
strains were prepared by washing spleens with 1 ml of RPML 1640 medium 
(GIBCO) followed by pressing through a 50 mesh stainless steel screen. 
Each recipient mouse received 0.2 ml of the spleen cell suspension. 
This suspension usually consisted of two donor spleens per eight 
recipient mice. Females were always used as donors and recipients. 
In this way, production of anti-HY antibody was avoided. Weekly in­
jections (usually at least 8) were given until good titers were pro­
duced. The recipient mice were always boosted 72 hours before the 
fusion. 
4. Fusion protocol 
The protocol used to produce hybridomas is a modification of the 
procedure described by Gefter et al.(1977). All the procedure was 
performed under strict sterile conditions. All glassware and instru­
ments were carefully sterilized (autoclaved). Three days before the 
fusion, NS-1 (or Sp-2/0) cells were transferred to fresh medium (usually 
4 to 6 flasks were enough for one fusion). 
This step is particularly important because fusions are more 
successful when the cells used are in logarithmic growth phase. As 
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mentioned earlier, mice were boosted the same day that the cells were 
transferred. 
The day of the fusion, one of the boosted mice was sacrificed and 
the spleen removed asceptically. The spleen was rinsed with serum free 
D-MEM. While holding the spleen with the forceps, 2 ml of medium was 
pushed through the spleen using a one ml tuberculine syringe. The 
cells were collected in a 60 x 10 mm sterile plastic petri dish. The 
spleen was then pressed through the sterile 50 mesh with the aid of 
forceps. The cell suspension was transferred into a sterile tube. 
Using a sterile red cell pipette (Fischer) and white blood cell 
diluting fluid (0.5% acetic acid, 0.1% [v/w] crystal violet), a 1:100 
dilution of the splenocyte suspension was made. The diluting fluid 
lyses erythrocytes and stains lymphocytes violet. Cells were counted 
with the aid of a hematocytometer. The NS-1 cells were washed and re-
suspended in serum-free D-MEM. The NS-1 cells were mixed in a one to 
five proportion with the splenocytes. Red blood cells were not re­
moved, but were discounted from the splenocyte cell count. The final 
concentration of cells was always between 4 and 5 x 10^ cells. 
A typical fusion would use 8 x 10^ NS-1 and 4 x 10^ splenocytes. 
The mixed cell population was centrifuged for 8 minutes at 200 x g at 
room temperature in 50 ml clear plastic, conical disposable tubes 
(Corning). 
Meanwhile, a 45% solution of PEG (polyethylen glycol 1540, Baker, 
Phillipsburg, NJ) was prepared by mixing 2.25 g of PEG with 2.75 ml 
of PBS, This PEG solution was prepared fresh for every fusion, melted 
in a water bath at 37°C and filter-sterilized using a 0.22 pm Millex 
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filter (Millipore, Bedford, MA). 
After centrifugation, the supernatant fluid was carefully removed and 
the cell pellet gently dispersed by taping the bottom of the tube. 
(For the addition of PEG during the fusion, the tips of 1 ml pipettes 
were sawed off and the pipettes sterilized. Pipettes prepared in this 
fashion proved to be useful since they do not disturb the clumps of 
cells which are needed for a successful fusion.) 
One ml of PEG solution per 8 x 10^ cells was slowly added for 45 
seconds, shaking the tube gently during the process. Next, the tube was 
incubated for 45 seconds at 37°C after which one ml of serum-free D-MEM 
was slowly added during one minute. 
Finally, during a period of 3 minutes, an additional 10 ml of serum-
free D-MEM was added while slowly shaking the tube. The tube was centri-
fuged 8 minutes at 225 x g at room temperature. After the second centri­
fugation, the supernatant was carefully removed and the cells resuspended 
in 1 ml of complete medium using the sawed off 1 ml pipettes. Cul­
ture medium was added to obtain a final concentration of 5 x 10^ 
cells/ml. Half the volume was then diluted to a concentration of 
2.5 x 10" cells/ml. Cells were plated at both concentrations by placing 
0.2 ml per well in 96 wells flat bottom plates (Linbro). Between 100 
and 120 wells were usually plated. 
Cells were fed 24 hours later with HAT (hypoxantine, aminopterin, 
thymidine) selective medium (see below). Feeding was achieved by care­
fully removing approximately 0.1 ml of medium from each well and re­
placing it with fresh medium. The procedure was repeated every 48 hours 
for two weeks. After this period, cells were fed with HT for an ad­
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ditional week, and then fed regularly with complete medium. 
Hybrid cells usually appeared between 7 and 14 days (sometimes 
as early as five days) after the fusion. Hybrid cells could 
be recognized as small groups of shiny, round, and healthy looking 
cells that frequently appeared in the edges of the wells. 
The wells were observed daily with the aid of an inverse micro­
scope. Wells were labeled when a group of hybrid cells were dis­
covered. 
Screening of cells was performed after two weeks of the fusion. 
Positive wells were transferred to 24 well plates (Corning) 
in 1 ml of complete medium. When cells were confluent, they were 
2 transferred either to 6 well plates (Linbro) or into 25 cm flasks 
in 3 ml of complete medium. At this stage, flasks were placed vertically 
to decrease surface area and enhance cell growth. When cells were 
confluent, the volume was increased to 10 ml and the flasks placed 
horizontally. Samples of all positive wells were frozen and stored. 
After transferring the cells at least twice, the hybridomas were 
cloned. 
5. Cloning 
a. Soft agar cloning Double strength medium was prepared by 
mixing 1/2 4 double distilled water with one package of powdered D-MEM 
(GIBCO) until dissolved. The medium was supplemented with the fol­
lowing compounds: 
a) 1% antibiotic/antimycotic 
b) 2.8 g of sodium bicarbonate 
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c) 1% glutamine (GIBCO) 
d) 0.5% garamycin (Schering). 
Medium was sterilized using 0.22 micron disposable filter units 
(Fischer). In a separate flask, 0.55 g of Bacto-Agar (DIFCO, Detroit, 
ML) was mixed with 40 ml of double distilled water and sterilized 
for 20 minutes. The agar was kept in a 570C water bath until used. 
Fifty ml of the double strength medium were mixed with 10 ml of 
fetal bovine serum and added to the 40 ml agar swirling quickly. 
Thirteen ml of the agar were poured into 15 x 10 mm disposable Petri 
dishes which were swirled to distribute the agar evenly and avoid 
bubbles. The plates were allowed to stand in the hood for about 3 
hours and then stored in the refrigerator for up to a week. The 
plates were placed in the 5% COg incubator for 1 to 2 hours before 
spreading the cells. One-tenth of one ml containing 10,000, 5,000, 1,000 
or 100 cells was added to individual plates and spread with a glass 
spreader previously dipped in 70% ethanol, flamed and cooled. After 
4 to 8 days of incubation, visible colonies could be observed and 
easily transferred into individual wells in 24 well plates containing 
one ml of complete medium. 
After 2 to 3 days, positive cells could be transferred into 4 ml 
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of medium in 25 cm flasks and incubated vertically as previously 
described. Cells were frozen or expanded for tumor production. 
b. Cloning by limiting dilution The appropriate cells were 
diluted to a concentration of 3 cells per ml. Cells were plated in 
96 well plates by adding 0.2 ml of cell suspension to every well. 
After 3 hours, wells were observed under the inverted microscope and 
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wells with more than one cell were omitted. After 8-10 days, cells 
were screened and ready to be transferred if positive. 
6. Preparation of selective medium 
Selective medium (HAT) was prepared according to the method of 
Littlefield (1964). Stock solutions of the three compounds were pre­
pared in Hanks balanced salt solution, filter-sterilized and frozen. 
The stock solutions were prepared as follows: 
Hypoxanthine (10 ^ M) 0.0136 g/10 ml (dissolved by placing the 
tube in a 40°C water bath) 
Aminopterin (5 x 10 ^ M) 0.0011 g/10 ml 
Thymidine (5 x 10 ^ M) 0.0121 g/10 ml 
(All three from Sigma.) 
Selective medium was prepared every week by adding 1 ml of the 
hypoxanthine stock solution and 0.2 ml of the aminopterin and thymidine 
solutions to 100 ml of complete medium. 
7. Expansion of cells and production of ascites fluid 
After cloning, positive cells were expanded by transferring them 
2 into 75 cm tissue culture flasks (Corning). When bigger flasks were 
used, 5 X 10^ cells were transferred into 30 ml of complete medium. 
For the production of ascites tumors, histocompatible recipient 
mice (at least 3 months old) were injected intraperitoneaily (i.p.) 
with 0.5 ml of Pristane (2,6-10,14-Tetra-Methylpentadecane, ICN Pharma­
ceuticals, Plainview, NY). Seven days later, the mice were injected 
i.p. with 2-10 X 10^ cells each. (For control ascites, BALB/c mice 
were injected with NS-1 cells.) Subcutaneous tumors were palpable after 
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2-3 weeks and ascites were collected using an 18 gauge needle. • The 
ascites fluid was centrifuged, and after incubating it for 1 hour 
at 500C, filtered and aliquoted. The aliquots were stored in the Revco 
freezer (-70OC). 
8. Screening methods 
a. Cytotoxicity test Ficoll-hypaque (Ficoll 400, Pharmacia, 
Uppsala; Hypaque, Winthrop, NY) used for lymphocyte separation was pre­
pared by mixing 62.7 ml of a 97» Ficoll solution with 37.3 ml of a 34% 
hypaque solution. Density was checked (p = 1.080), the solution ali­
quoted and kept at -20°C. Ten ixl of Ficoll-hypaque isolated spleen 
cell suspension (6 x 10^ cells/ml) were mixed with 10 p.1 of medium from 
each of the wells (or the proper dilution of ascites). Next, 10 nl 
of a 1:2 dilution of guinea pig serum were added as the source of comple­
ment. The mixture was incubated at 37°C for 1 hour after which time 
10 |il of a 0.4% filtered trypan blue solution (GIBCO) were added. The 
percent of cytotoxicity was scored by counting 200 cells and comparing 
that to a control population of cells (usually from the donor strain 
used for the immunization). More than a 20% difference in cytolytic 
titer was considered positive. 
b. Two-step microcytotoxicitv test A modified two-step 
microcytotoxicity (Kennet, 1980) was developed with the purpose of 
analyzing a larger number of cells. 
The supernatants to be tested were aliquoted in 5 p,l amounts in 
microtiter plates (Falcon 3034, Fisher Scientific). Ficoll-hypaque 
isolated, target splenocytes were washed in a 0.1% BSA (bovine serum 
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albumin, Sigma) in RPML 1640 and suspended to approximately 2 x 10^ 
cells/ml. One p.1 of the cells to be tested were added to each well 
and incubated with the supernatant for 30 minutes at room teiqperature. 
Next, 5 pi of a 1:2 dilution of guinea pig complement (GIBCO) were 
added and incubated for one hour at room temperature. The percent of 
killed cells was scored using an inverted microscope after adding one 
pl of a 0.4% trypan solution to each well. 
Since only some classes of antibody fix complement and cytolysis 
depends on antigen density and/or distribution, only certain mono­
clonal antibodies are cytolytic. Noncytolytic antibody was detected 
by adding a second antibody. 
Thus, after the first 30 minutes of incubation, 2 pi of a 1:4 
dilution of rabbit anti-mouse IgG (specific for heavy chains) (Litton 
Bionetics) were added and incubated for an additional 30 minutes, prior 
to the addition of complement. 
c. Indirect immunofluorescence using L-929 fibroblasts • Murine 
L-929 fibroblasts express H-2 antigens (Manson and Palm, 1972), They do 
so because they were originally isolated from C3H mice (Sanford et al., 
1948) which express the H-2 haplotype. These cells were the ideal 
target cells for the screening of anti-H-2 monoclonal antibodies. The 
number of screened wells using this method was smaller than using the 
two-step microcytotoxicity test. 
L-929 mouse fibroblasts were obtained from Dr. J. Thomas, Iowa 
State University, and grown in serum free, antibiotic free Waymouth's 
medium (GIBCO). Every 5 days (when cells were confluent), cells were 
scraped using a sterile rubber policeman and resuspended in 5 ml of 
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fresh medium. Next, 0.5 ml of the cell suspension were transferred to 
2 
4.5 ml of medium in a different 25 cm flask. Cells were also incubated 
at 37°C and 5% 00% in air. 
d. Cell fixation Seven to eight glass coverslips (8 mm x 
8 mm) were overlayed in the bottom of a plastic petri dish. Confluent 
cells were scraped and diluted one to ten in fresh medium. The cover-
slips were covered with 10 ml of the cell suspension and incubated for 
3 hours. After this time, most cells were attached to the cover-
slips. 
In this way, up to 40 coverslips could be prepared with one flask 
of cells. Cells were fixed for 3 minutes using a solution of 95% 
ethanol and 5% acetic acid. At this stage, the coverslips could be 
stored in the freezer for several weeks. For the screening, the 
coverslips were covered with 0.2 ml of the supernatants and incubated 
in a humidified chamber at 37°C. 
After 1 hour, coverslips were washed with PBS for 15 minutes in 
individual beakers. The coverslips were dried and incubated for another 
hour with 0.2 ml of the appropriate dilution of FITC (fluorescein-
isothiocyanate) conjugated goat anti-mouse IgG (Cappel Lab, Cochranville, 
PA). Coverslips were washed individually with PBS and mounted in slides 
using a drop of 50% glycerin solution in PBS. 
Cells were observed under incidence illumination using a Zeiss 
microscope equipped with a IVFI Epi-fluorescence condenser (Merz 
Optical, Chicago, IL). 
e. Indirect immunofluorescence usine lymphocytes Fluorescent 
staining of lymphocytes was done using a modification of the method 
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described by Kenney and Lawton (1975). Lymphocytes obtained as pre­
viously described (i.e., ficoll-hypaque) were washed twice with ice cold 
PBS. Cells were suspended at a concentration of 1 x 10^ cells/ml in 
1% FBS (fetal bovine serum) in PBS and deposited on slides and incubated 
for 30 minutes at 4°C to let cells settle on the slide. Smears were 
briefly air-dried and fixed for 15 minutes in 5% acetic acid 95% ethanol 
in a cold room (4°C). The fixed cells were then washed in PBS ând in­
cubated with the monoclonal supernatant for 30 minutes. After the slides 
were washed with PBS, they were incubated 1 hour with appropriate dilution 
(usually 1:120) of FITC conjugated goat anti-mouse IgG at 37°C in a moist 
chamber. The slides were washed in PBS and mounted in one drop of 50% 
glycerol in PBS. Slides were observed first under phase contrast and 
then under incidence illumination. 
Pictures were taken by using a camera with fast Kodacolor (400 ASA, 
Kodak) film. Exposure time ranged from 20 seconds to 2 minutes. The 
optimal exposure time was usually between 30 and 45 seconds. 
9. Purification of monoclonal antibodies 
a. Protein A sepharose chronatographv Purification of mono­
clonal antibodies from concentrated supernatant was achieved using 
protein A sepharose chromatography according to the method described 
by Ey et al. (1978). 
Staphylococcal protein A covalently linked to sepharose was ob­
tained from Pharmacia Fine Chemicals (Uppsala) swollen in 10 mM PBS 
(pH 8.0) containing 0.1% sodium azide and packed into a 300 x 15 mm 
glass column. The column was stored and used in a cold room (4-5°C). 
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Buffer solutions used were either 0.14M sodium phosphate (pH 8.0) or 
O.IM sodium citrate-citric acid (pH 3.0). Before use, the column was 
washed and equilibrated with pH 3.0 buffer. The column was used several 
times without change in binding properties. 
Hybridoma supernatant was concentrated between 20 and 40 times using 
a 180 ml (or 50 ml) agitated ultrafiltration unit with a XM50 membrane 
(excludes molecules smaller than 50,000 daltons) (Amicon, Lexington, 
Mass.). 
Two-and-a-half ml of the concentrated supernatant was diluted with 
2.5 ml of the pH 8.0 phosphate buffer and applied to the column. The 
column was washed with pH 8.0 buffer until no absorbance was read at 
280 nm. The pH 3.0 buffer was then applied and fractions collected 
every 10 minutes. These fractions were collected in tubes containing 
0.8 M tris-HCl, pH 9.0. The of each fraction was measured. 
Zou uni 
A sample of each fraction showing absorbance was placed in double dif­
fusion (Ouchterlony) plates and run against rabbit anti-mouse IgG 
to confirm the presence of antibody. The positive fractions were 
pooled and the protein concentration was calculated from the absorbance 
of the solution at 280 nm assuming an extinction coefficient (1% 
w/v, 1 cm) of 14. 
b. Ammonium sulphate precipitation of ascites A saturated 
solution of (N^)was prepared by adding 383.5 g of crystals to 
500 ml of distilled water and stored at room temperature for 8 hours. 
When most of the salt was dissolved, the solution was allowed to 
stand at 5°C overnight and pH adjusted to 7.1 with 30% (w/v) NaOH 
(sodium hydroxide). A 50% saturation was used to precipitate mono-
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clonal antibodies from ascites fluid. 
One volume of saturated ammonium sulfate solution was added drop-
wise to one volume of millipore filtered ascites while swirling. 
Precipitation was allowed to occur for 1 hour. The precipitate was 
collected by centrifugation at room temperature and 3000 rpm (Beckman 
centrifuge model TJ6) for 30 minutes and dissolved to the original 
volume with PBS. The procedure was repeated twice. After the last 
precipitation, the precipitate was dissolved in a small volume of PBS 
and dialyzed against several changes of PBS (pH 7.0). The solution was 
aliquoted in small freezer vials and kept at -70OC. 
10. Immunoglobulin class and subclass analysis of monoclonal anti­
bodies 
Class and subclass specific rabbit anti-mouse serum was obtained 
from Litton Bionetics (Kensington, MD). Double diffusion plates 
(Ouchterlony) were prepared using 1% agarose, 0.1% sodium azide in 
PBS. Fifteen iil of concentrated monoclonal supernatant (supernatant 
was concentrated at least 10 times by the method described earlier) 
were placed in the center well. In the surrounding wells, 15 m-I of 
each specific antisera were placed and the plates were incubated 24 
hours at room temperature after which single precipitation bands 
could be observed. 
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F. Detection of H-2 Antigens on Preimplantation Embryos 
1. Indirect immunofluorescence 
Embryos of the appropriate strain were collected as previously 
described at 113 and 96 hours after HCG injection. Embryos were 
washed in WB medium 3 times and then treated with a 0.25% solution of 
pronase (Sigma) for about 5 minutes to remove the zona pellucida. After 
the enzyme treatment, embryos were again washed 3 times in WB. Labeling 
of embryos was done using the procedure of Palm et al. (1971). Embryos 
were incubated with 0.2 ml of different dilutions of monoclonal ascites 
for 30 minutes at 37°C and 7% CO2. After the incubation, the embryos 
were washed 3 times in WB in order to remove unbound antibody. Next, 
the embryos were incubated with 0.5 ml of a suitably diluted fluoroscein-
conjugated goat anti-mouse IgG (Cappel, Cochranville, PA) for 1 hour. 
Embryos were again washed 3 times in WB to remove excess conjugate. 
A few bias tomeres became separated during the washing but the majority 
remained intact. 
For observation, the embryos were placed on a slide and mounted 
using a 50% solution of glycerol and PBS. To avoid distortion of the 
blastomers, small pieces of tape were placed in between the slide and 
the coverslip. The same procedure was used with embryos with the zona 
intact. 
2. Embryo cytotoxicity assay 
The method described by Cozad and Warner (1981) was used for the 
detection of H-2 antigens on embryos. Based on the same principle 
as the lymphocyte cytotoxicity assay, this method measures cell death 
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by a reduction in DNA synthesis, measured by the incorporation of 
tritiated thymidine. 
Before every assay, 25 pi of WB medium was placed in each well 
of a 96 well, flat-bottom plate (Linbro). From 3 to 5 embryos were 
placed in each well using a finely drawn pipet. Next, 25 y.1 of the ap­
propriate serum or ascites dilution were placed in the well (25 p-l of medi­
um of normal mouse serum in the case of controls). Plates were incubated 
for 1 hour at 370C and TU CO2. (All incubations for embryo experi­
ments were in a humidified chamber at 37°C and TL COg in air.) Finally, 
25 pi of a 1:2 dilution in WB medium of, fresh guinea pig serum were 
added to the wells. After 1 more hour of incubation, 75 y.1 of 
3 3 
a H-thymidine solution containing 8 pCi/ml in WB medium ([methyl H] 
thymidine 20 Ci/mmol, aqueous solution. New England Nuclear, Boston, 
Mass.) were added to each well and incubated for an additional period 
of 5 hours. The reaction was terminated by placing the plate on 
ice. The contents of the wells were harvested with a Titertek cell 
harvester (Flow) using distilled water for the washing and a 50-50 cm/Eg 
vacuum. The glass fiber filter papers were dried at 65°C for 20 
minutes or at room temperature overnight. . Radioactivity was counted in a 
liquid scintillation counter using toluene fluor (18.6 g PPG, [2,5-
dyphenyl oxazole] and 0.94 g POPOP [p-bis-]2-(5 phenyloxazolyl)]-
benzen] per 3.8 liters of toluene). After removal of the papers, 
the fluor was reused several times. The experimental data (minus 
background cpm) were then expressed as % inhibition of thymidine 
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3. Indirect embryo cytotoxicity test 
To amplify the effect of the antibody and also to eliminate non­
specific serum effects by using higher dilution serum concentration, 
an indirect test was developed. A series of block experiments was 
designed in which dilutions of alloantisera (A/J anti-DBA/2) ranging 
from 1:4 to 1:64 were reached with dilutions of rabbit anti-mouse IgG 
(prepared in our laboratory) ranging also from 1:4 to 1:64. 
Embryos were basically treated the same way as in the direct 
test previously described. In this case, however, after the serum 
incubation, the embryos were incubated an extra 30 minutes with the 
appropriate dilution of rabbit anti-mouse (NH^)fraction. Comple-
3 
ment was added and after an hour, 100 \sl of H-thymidine solution were 
also added. Embryos were harvested as previously described. 
G. Indirect Test Using Thymocytes 
This test was devised to find the optimal dilutions of both allo­
antisera and rabbit anti-mouse immunoglobulin antibody. Thymocytes were 
used to avoid nonspecific killing by the rabbit antiserum. 
The thymuses from two DBA/2 mice (4-6 weeks) were removed and 
placed in a petri dish containing RFMI 1640. Each thymus was cleaned 
by removing nodes and blood vessels and transferred to another petri 
dish containing fresh medium. Two ml of medium were injected into the 
thymus which was then teased with forceps and put through a stainless 
steel mesh. The dissociated cells were transferred to a tube and allowed 
to settle for 5 minutes. After discarding the clumps, the cells were 
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transferred to a centrifuge tube and pelleted at 200 x g at room tempera­
ture in a TJ-60 centrifuge (Beckman) (approximately 900 rpm) for 10 
minutes. The cells were washed and diluted to 6 x 10^ cells/ml. (One 
Q 
thymus usually yielded 2 x 10 cells.) Ten pi of the cell suspension 
were added to each test tube and incubated for one hour at 37°C with 
the appropriate dilution of alloantisera. Tubes were then incubated 
for 30 minutes with the different dilutions of rabbit anti-mouse anti­
body ( (NH^) fraction) before adding the guinea pig complement. Dead 
cells were scored as in the regular cytotoxicity test already described. 
H. Statistical Analyses 
Significant differences of mean cell number per embryo among strains 
were assessed by Student "t-tests." For the kinetic studies, statistical 
differences in the slopes of the rate of development were found using 
multiple regression analysis. Data were treated as a special type of 
split-plot arrangement in which one of the variables is time (Snedecor 
and Cochran, 1980), The data were organized as shown in Table 26 and fed 
into the computer. 
Data were analyzed using SAS (Statistical Analysis System) and a 
General Linear Models procedure (PROC GLM). The dependent variable 
was Logg Cell Number Embryo (LCN) while the independent variables were 
strain (C54BL/10Sn, BIO.BR and C57BR/cdJ) and time (hours post HCG). 
Each time point had replications (number of experiments) and in each 
experiment, a certain number of embryos were scored. All these sources 
of variation are accounted in the analysis of variance. The model 
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statement used was: 
Classes strain; 
Model LCN = strain hour (strain)/solution. 
Through this analysis, linear equations were obtained for the three 
strains. The coefficients were then compared using a Student "t-test." 
For the analysis of the Fl, F2 and backeross data, the number of 
cells per embryo was converted to a logarithmic number to achieve a 
better graphic representation of the data. Logg was used instead of 
log^Q since the embryos undergo doubling cleavage divisions during 
development. A plot of logg cell number/embryo was then made versus 
the relative frequency (percentage of total) of embryos of a given cell 
number. Relative frequency histograms were chosen because the number 
of embryos in each cross was different, so the only way to compare them 
was to graph them according to their relative frequency (Steel and Torrie, 
1980). 
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III, RESULTS 
A. Effect of the H-2 Complex on Early Development 
1. Development of the Tarkovski method using CFl embryos 
Using the Tarkovski method, data were first collected using CFl 
embryos. Although the method can be tedious, enfljryos can be analyzed 
individually. Figure 1 shows a blastocyst fixed by the Tarkovski 
method. The nuclei are stained blue and can be easily counted. It 
can be observed that some of the cells on the slide are in metaphase. 
Figure 2 shows the data collected with CFl embryos and plotted as log2 
of cell number versus time after hCG injection. The correlation coef­
ficient is 0.99 showing the accuracy of the method. The data used for 
this figure are shown in Table 2. The success rate obtained vith the 
method vas up to 90% vith "8 cell" stage embryos and 70% vith morulas 
and blastocysts. 
It 2. Association of slov development vith H-2 haplotvpe 
Experiments vere designed to assess the number of cells per embryo 
in a variety of inbred strains expressing different H-2 haplotypes 
(Tables 3 and 4). The times of development chosen vere 65 hours 
post hCG which corresponds to "8 cell" stage (mostly "4 cells" in the 
slow-developing strains) and 89 hours post hCG which is the blastocyst 
stage (morula stage for slow-developing strains). 
V 
The data presented in Tables 3 and 4 show that H-2 haplotype mice 
develop more slowly than the other haplotypes tested. Using a "t" 
student test, statistical differences were found between all the H-2 
strains and the rest of the strains at 89 hours post hCG (Table 3). 
Figure 1. Picture of a CFl blastocyst (89 hours post hCG) fixed by 
the Tarkowski method 
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Figure 2. Correlation between cell number (CFl embryos) and time post 
hCG injection. Data were collected using the Tarkowski 
method 

49 
Table 2. Number of cells per embryo in CFl mice after different 
times of collection. Data were obtained using the Tar-
kowski method. Raw data are shown in Tables 24 and 25 
(see Appendix A) 
Time post 
hCG (hrs) No. expts. 
No. embryos 
scored 
Mean cell No./ 
embryo (S.E.) 
47 1 55 to
 O
 
53 1 59 3.6 (0.1) 
56 1 73 4 (0) 
65 4 50 6.8 (1.0) 
89 5 51 44.4 (2.2) 
Ic 
Table 3. Association of H-2 haplotype with slow development (65 
hours post hCG). Raw data are shown in Tables 27 , 28, and 
29 (see Appendix A) 
Mouse 
strain 
H-2 
haplotype 
No. embryos No. Mean cell No./ 
scored expts. embryo (S.E.) 
A^ a 47 8 6.7 (0.2) 
C57BL/10Sn^ b 63 3 ; 7.6 (0.2) 
DBA/2 d 91 1 6.9 (0.4) 
CBA® k 45 5 4.4 (0.2)* 
C3H/He k 48 ] 6.4 (0.1) 
C57BR/cdj k 44 : > 4.7 (0.3)* 
DBA/1* q 56 : 1 7.1 (0.3) 
SJL® s 46 : 1 7.1 (0.3) 
^Data collected by K. Verbanac (Biochemistry and Biophysics De­
partment, Iowa State University). 
^Significantly lower than the other inbred strains (p <0.05). 
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Table 4. Association of slow development with the H-2^ haplotype (89 
hours post hC6). Raw data are shown in Tables 30, 31, and 
32 (see Appendix A) 
Mouse H-2 No. embryos No. Mean cell No./ 
s train haplotype scored expts. embryo (S.E.) 
A* a 54 4 32.9 (1.5) 
C57B2/10Sn* b 48 8 33.1 (2.1) 
DBA/2 d 53 2 30.5 (1.4) 
CBA* k 45 7 18.9 (1.0)** 
C3H/He k 40 1 24.3 (0.4)** 
C57BR/cdj k 55 2 18.7 (1.0)** 
DBA/1* q 47 8 30.2 (1.5) 
SJL* s 48 5 31.9 (2.0) 
^Data collected by K. Verbanac (Biochemistry and Biophysics De­
partment, Iowa State University). 
**Significantly lower than the other inbred strains (p <0.01). 
However, the three strains of H-2^ haplotypes (CSA, C32 and C57BR/cdj) 
were not statistically different from each other. The degrees of 
freedom were based on the number of experiments rather than the number 
of embryos scored. 
3. Proof of association using congenic mice 
To formally test if the effect studied was linked to the H-2 
complex, two groups of congenic mice were used (Table 5, Figures 3 
and 4). It is clear from Table 5, Group A, that changing the genetic 
composition of a mouse only at the H-2 complex (that is, from H-2^ 
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Table 5. Use of congenic strains to prove association of slow develop­
ment with the H-2^ haplotype. Raw data shown in Tables 33 
and 34 (see Appendix A) 
H-2 
Mouse haplo­ Background No. embryos No. Mean cell No./ 
strain type haplotype scored expts. embryo (S.E.) 
Group A 
C57BR/cdj k C57BR/cdJ 55 2 18.7 (1.0) 
C57BL/10Sn b C57BL/10Sn 48 8 33.1 (2.1) 
BIO.BR^ k C57BL/10Sn 50 6 22.8 (1.3)* 
Group B 
C57BL/10Sn b C57BL/10Sn 48 8 33.1 (2.1) 
C3H/He k C3H/He 40 1 24.3 (0.4) 
C3H.B10 b C3H/He 35 3 31.5 (0.6)** 
^ata collected by K. Verbanac (Biochemistry and Biophysics De­
partment, Iowa State University). 
*Significantly lower than congenic strain C57BL/10Sn at p < 0.001 
level. 
**Significantly higher than congenic strain C3H/He at p <0.001 
level. 
to H-2 ) changes its development from fast to slow. The reciprocal 
group (group B, Table 5) confirms this observation. In this case, 
Ir 
changing the genetic composition of the H-2 complex from H-2 to 
H-2^ changes the development from slow to fast. The above data 
is summarized graphically in Figures 3 and 4. 
It is clear (especially from the 89 hours data) that the intro­
duction of a different H-2 haplotype in the same background changes 
dramatically the speed of development. Undoubtedly, the H-2 complex 
has a definitive influence on the rate of development. In a previous 
report (Verbanac & Warner, 1981), the H-2 associated gene(s) was named 
Figure 3. Graphie representation of association of slow development 
with H-2^ haplotype (65 hours post hCG) 
MEAN CELL NUMBER/EMBRYO 
39 
> 
«mm 
z 
:Cj57BL/10Sn 
C57BR/cdJ 
BIO.BR 
C3H.B10J-
C3H/HeJ 
I 
lO 
Figure 4. Graphie representation of the association of H-2^ haplotype 
with slow development (89 hours post hCG) 
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Ped for preimplantation embryo development. 
The above data were analyzed indepth in Table 6a. Only one P value 
in the table is not exactly as expected. The C57BR/cdj and BIO.BR 
strains are both H-2 but differ at the P < 0.05 level. This may be 
evidence that background genes, as well as H-2 linked genes influence 
early embryonic development. This last observation will later be 
confirmed with the first cleavage division experiments (see below). 
4. Earliest action of Ped gene 
a. Ovulation time Experiments were planned to find the 
earliest action of the Ped gene(s). 
The first set of experiments was directed to find out if the 
Ped gene(s) influenced time of ovulation. The three strains listed 
in Group A (Table 5) were used (C57BR/cdj, C57BL/10Sn and BIO.BR). 
The data are summarized in Figure 5. No real differences in ovulation 
time were observed. All three strains ovulate within 2 hours of 
each other, so that the H-2 associated gene(s) does not express itself 
at this time. Two types of eggs were found in the oviducts. One 
type was surrounded by cumulus cells, and, thus, recently ovulated. 
The other eggs found were denuded of cumulus and were eggs matured under 
the female ovarian cycle. These eggs were excluded from the 
data. Time of mating and time of fertilization were not measured. 
However, it has been shown (Esworthy, 1979) that ova fertilized 
synchronously using artificial insemination maintain differences in 
cell number at 89 hours post hCG. 
b. Time of first cleavage division Next, it was determined 
if the Ped gene(s) had any influence on the time of first cleavage 
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Table 6a. Comparison of cell number per embryo among inbred and con-
genic strains 
Comparison P 
C57BL/10Sn vs. C57BR/cdj < 0.001 
C57BL/10Sn vs. BIO.BR < 0.001 
C57BL/10Sn vs. C3H.B10 N.S.^ 
C57BL/10Sn vs. C3H < 0.01 
C57BR/cdj vs. BIO.BR < 0.05 
C57BR/cdj vs. C3H.B10 < 0.001 
C57BR/cdj vs. C3H N.S. 
BIO.BR vs. C3H.B10 < 0.001 
BIO.BR vs. C3H N.S. 
C3H.B10 vs. C3H < 0.001 
^ values are based on student's t-test analysis of the data 
shown in Figure 1. 
^N.S. = not significant. 
division. The results of these studies are shown in Figure 6. The 
graph shows that this is the first step in development, which we have 
studied, in which the influence of the H-2 linked Fed gene(s) is 
clearly observed. First cleavage division starts 6 hours earlier 
in the C57BL/10Sn strain than in the C57BR/cdj. However, the congenic 
strain (BIO.BR) falls between the slow (C57BR/cdj) and the fast 
(C57BL/10Sn) developing strains. This, as we already pointed out, 
is probably due to the presence of background genes that together 
Figure 5. Time of ovulation of C57BL/10Sn (o), BIO.BR (a), and 
C57BR/cdj (a) mice 
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with the H-2 linked Fed gene influence the time of first cleavage 
division. 
5. Rate of development 
With the purpose of investigating, if the Ped gene had any ef­
fect on the rate of development, additional cell number determinations 
were done at 47, 53, and 56 hours post hCG. All the data collected 
were plotted in Figure 7 and analyzed as previously described in the 
Materials and Methods section. The statistical analysis shows that 
the slope of the C57BL/10Sn (H-2^) line is different (p < 0.01) from 
the C57BR/cdj (H-2^) and BIO.BR (H-2^) slopes. The latter two 
slopes were found to be statistically identical. Thus, the Ped 
gene(s) besides influencing the time of first cleavage division, 
influences the subsequent rate of development, too. Based on these 
observations, a theoretical curve was generated (Figure 8). The curve 
explains the wide differences encountered between strains and why the 
65 and 89 hours time points gave consistent differences between the 
fast and slow strains. It is clear that it would be possible to pick 
points (e.g., 70 hours) in which the apparent rate of development would 
seem to be the same between the fast and the slow strains. Of course, 
in reality, the step function would be curved, since cell division is 
somewhat asynchronous after the first cleavage division. Analysis of 
more points than those shown in Figure 7 should lead to curves similar 
to the theoretical step functions shown in Figure 8. 
Figure 7. Rate of development of C57BL/10Sn (o), BIO.BR (a) and 
C57BR/cdj embryos. (The equations of the lines are the 
following: C57BL/10Sn,' y = -3.26 + 0.0934%; BIO.BR, 
y = -2.64 + 0.0807x; and C57BR/cd.i, y = -2.75 + 0.0763%.^' 
Raw data used in the statistical analyses are presented 
in Table 26, Appendix A.) 

Figure 8. Theoretical curve showing development of a slow and a 
fast strain 
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6. Genetic analysis 
a. F]_ generation All the genetic analyses were performed using 
the "fast" C57BL/10Sn and its congenic, "slow," strain BIO.BR. In this 
way, background genes were eliminated as much as possible and segrega­
tion could be more readily observed. The first generation to be studied 
was the generation. The results of the two possible crosses (see 
Table 9) are shown in Tables 6b and 7. It is seen from Table 7 that H-2 
linked Fed genes show dominant expression of the fast development pheno-
type. Since both F^ crosses gave similar results, there is no evidence 
for any maternal effect on Fed gene(s) expression. 
b. £2 generation F^ mice were bred in our laboratory and 
crossed to produce F^ generation embryos. The four types of possible 
Fg crosses were generated (Table 8). No differences were found between 
the four crosses (Table 8). Thus, the embryos of the four crosses were 
Table 6b. Analysis of F]^ generation embryos (65 hours post hCG). Raw 
data are presented in Tables 35 and 36 (see Appendix A) 
Source of No. of No. of Mean cell No./ 
embryos expts. embryos embryo (S.E.) P 
C57BL/10Sn 3 63 7.6 (0.2) -
BIO.BR 2 59 6.0 (0.3) < 0.01* 
F^ Cross 1 2 46 7.1 (0.3) N.S.** 
F^ Cross 2 1 39 6.8 (0.3) N.S. 
^Comparison to C57BL/10Sn by Student's "t"-test. 
**N.S. = not significant. 
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Table 7. Analysis of generation embryos (89 hours post hCG). (Data 
collected by K. Verbanac, Biochemistry and Biophysics De­
partment, Iowa State University) 
Source of No. of No. of Mean cell No./ 
embryos expts. embryos embryo (S.E.) P 
C57BL/10Sn 8 48 33.1 (2.1) -
BIO.BR 6 50 22.8 (1.3) < 0.01* 
F^ Cross 1 5 41 29.7 (1.6) N.S.** 
F^ Cross 2 5 60 28-6 (1.2) N.S. 
*Comparison to C57BL/10Sn by Student's "t"-test. 
**N.S. = not significant. 
Table 8. The number of cells per embryo in the four possible ?£ 
crosses. Data are shown in Tables 37, 38, 39, and 40 (see 
Appendix A) (89 hours post hCG) 
Mean cell No./ 
crosses embryo (S.E.)^ 
^2 
Cross 1: 
^1 
Cross X Cross l<f 24.2 (1.4) 
^2 
Cross 2: Cross 2  ^ X Cross lo^ 24.4 (1.5) 
^2 
Cross 3: Fl Cross 2$ X Fl Cross Idf 26.4 (1.5) 
^2 Cross 4: Fl Cross X Fl Cross 2a» 24.8 (1.4) 
^All four crosses were compared with each other. No statistical 
differences were found among them. 
69 
pooled and data plotted, as shown in Figure 9, together with several 
other crosses described below. The theoretical distribution and genetic 
analysis of all crosses are shown in Table 9. In Figure 9, all experi­
mental observations were plotted as frequency histograms of Logg cell 
number. Parental crosses (P^ = C57BL/10Sn), (P^ = BIO.BR), F^, F^ 
and backcrosses were all aligned as frequency histograms in the same 
figure to facilitate comparison and analysis. As already mentioned, 
frequency histograms were the only way to compare all the distributions 
since they all have different numbers of observations (see Table 7). 
Backcrosses were also generated against both parental strains and 
plotted in the same figure. Backcrosses were chosen because their 
segregation patterns are sometimes more clear than F^ generations. The 
histograms agree very closely with the theoretical distribution of 
phenotypes described in Table 7. The variance in P^ and F^ must 
be environmental, whereas the variance in F^ and the backcrosses is 
presumably due to segregation of genes. As expected, the mean of the 
F2 embryos (25.0) is statistically equal to the mean of the two back-
crosses (25.9). Also, as expected, variance increases in the F2 
generation while the distribution of the F^ generation is more com­
pact (Figure 9). 
7. Comparative development of congenic mouse strains 
In order to study the range of allele of the H-2 linked Ped 
gene, six more congenic strains were analyzed. As can be observed from 
Tables 10 and 11, the only other strain showing slow development is the 
BIO.RIII (H-2^). 
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Table 9. Mouse embryos analyzed 
H-2 No. embryos 
Source of embryos haplotype scored 
Inbred and congenic strains 
C57BL/10Sn b 48 
C57BR/cdj k 55 
BIO. BR k 50 
C3H.BI0 b 35 
C3H/He k 40 
crosses 
F^ Cross 1: C57BL/l0Sn? x B10.BR<? b/k 41 
F^ Cross 2: BlO.BRf x C57BL/10Sncf» k/b 60 
F2 crosses 
F2 Cross 1: Cross 1? X 
^1 
Cross Id* — 48 
F2 Cross 2: Cross 2$ X 
^1 
Cross lo» — 39 
F2 Cross 3: 
^1 
Cross 2$ X ?! Cross 2d* — 53 
F^ Cross 4: 
^1 
Cross 1? X Fl Cross 2d* — 45 
Total lk/k:2k/b:lb/b 185 
Backcrosses 
Backcross 1: BIO.BR? x F^ Cross lo* lk/k:lk/b 34 
Backcross 2: C57BL/10Snf % F^ Cross là* lk/b:lb/b 33 
Figure 9. Frequency histograms of P2, F^, F2, and backcrosses. 
(Raw data used to build the histograms are presented in 
Tables 37, 38, 39, 40, 41, and 42, Appendix A.) 
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Table 10. Comparative development of congenic mouse strains (65 hours 
post hCG). Raw data are shown in Tables 43 , 44 , 45, and 46 
(see Appendix A) 
Mouse 
strain 
H-2 
haplotype 
No. embryos 
scored 
No. 
expts. 
Mean cell No./ 
embryo (S.E.) 
C57BL/10Sn^ b 63 3 7.6 (0.2) 
BIO.A* a 153 3 6.7 (0.2) 
B10.D2 d 47 2 6.5 (0.3) 
BIO.BR* k 59 2 6.0 (0.3)* 
BIO.Q q 37 1 7.4 (0.2) 
BIO.RIII r 39 2 5.6 (0.4)* 
BIO.S* s 51 3 8.0 (0.4) 
BIO.PL u 18 2 7.0 (0.6) 
^Data collected by K. Verbanac (Biochemistry and Biophysics De­
partment, Iowa State University). 
^Significantly lower than the background strain at p < 0.05. 
8. Effect of background genes 
As has already been shown, there is an influence of background genes 
on the first cleavage division and rate of development in general. This 
was made even more evident when congenic mice of a different background 
(BALB/c) were used. Data were observed from three different congenic 
strains. The three of them had different independent haplotypes but 
shared the same background. Regardless of the haplotype, all three 
strains showed slow development (Table 12). This is especially 
significant since BALB.B and BALB/c (H-2^ and H-2^) carry "fast" 
development haplotypes. This points to the presence of background 
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Table 11. Comparative development of congenic mouse strains (89 hours 
post hCG). Raw data are shown in Tables 47, 48, 49, and 50 
(see Appendix A) 
Mouse H-2 No. embryos No. Mean cell No./ 
strain haplotype scored expts. embryo (S.E.) 
C57BL/10Sn* b 48 8 33.1 (2.1) 
BIO.A® a 65 3 32.0 (1.1) 
B10.D2 d 47 2 39.1 (1.5) 
BIO.BR^ k 50 6 22.8 (1.3)* 
BIO.Q q 34 2 30.2 (1.3) 
BIO.RIII r 46 2 25.4 (0.9)* 
BIO.S* s 28 3 33.8 (2.4) 
BIO.PL U Vi 35 3 30.4 (1.7) 
^Data collected by K. Verbanac (Biochemistry and Biophysics De­
partment, Iowa State University). 
*Significantly lower than background at p < 0.01. 
genes influencing development. However, it has to be emphasized that the 
mean cell number/embryo of the BABL.K strain was statistically lower than 
the other two congenic strains at 89 hours post hCG (see Table 12). Thus, 
the presence of the slow Fed allele (H-2 ) retarded embryo development even more. 
9. Gene complementation studies 
Two slow strains were mated to test for possible gene complementa­
tion. Reciprocal crosses were done between CBA and BALB/c mice both of 
which showed slow development in the previous experiments. The data 
collected are shown in Table 13. No evidence of gene complementation or 
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Table 12. Effect of background genes on embryonic cleavage rate. 
Raw data are presented in Tables 51, 52, 53, 54, 55, and 
56 (see Appendix A) 
Mouse H-2 No. embryos No. Mean cell No./ 
strain haplotype scored expts. embryo (S.E.) 
65 hours post hCG 
BALB/c d 50 3 4.5 (0.2) 
BALB.B b 46 1 4.1 (0,1) 
BALB.K k 65 1 4.3 (0.03) 
89 hours post hCG 
BALB/c d 49 4 22,0 (1.4) 
BALB.B b 32 1 23.1 (2.8) 
BALB.K k 65 1 18.1 (0.8)* 
^Significantly lower than BALB/c at p <0.05. 
Table 13. Studies on gene complementation. Raw data are shown in 
Tables 57, 58, 59, and 60 (see Appendix A) 
H-2 No. embryos No. Mean cell No./ 
Cross haplotype scored expts. embryo (S.E,) 
65 hours post hCG 
CBAg^ X BALB/cd^ k/d 39 2 3.6 (0.1) 
BALB/cg X CBAcf* d/k 30 1 4.9 (0.1) 
89 hours post hCG 
CBAg X BALB/co^ k/d 28 3 18.3 (1.2) 
BALB/c^ X CBAo* d/k 47 2 23.5 (0.9) 
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maternal egg influence was found. Both crosses are statistically 
identical. 
B. Production of Monoclonal Antibodies 
1. Nomenclature of monoclonals 
The first two characters correspond to the first well that was 
positive during the first screening. The number immediately following 
corresponds to the number of plate. The last letter and number 
correspond to the well where the cells were taken after being cloned. 
For example: 2H1-5B .2Eis the original positive well of the first 
plate (1). 5B is the well in which the cells were grown after 
cloning and screening for the second time. Monoclonal antibodies 11-4.1 
were obtained from cells received as a gift of the Salk Institute, Thus, 
their nomenclature was kept for this particular monoclonal. 
A summary of all fusions is shown in Table 14. The following ob­
servations can be made from the table: 
1) The most successful fusions were done with NS-1 cells. Al­
though fusion 4, which used Sp-2/0 cells, gave a good rate of hybridiza­
tion (65%), for the most part, Sp-2/0 did not give good results. In 
fusion 6, they did not fuse at all, probably due to the presence of 
mutants. The Sp-2/0 cells were very unstable and needed to be treated 
every 3-4 weeks with S-azaguanine. In the case of fusion 10, the lack 
of hybridization could be due also to the presence of mutants. 
2) The fusion protocol per se worked fairly well since good 
hybridization rates were obtained in most fusions. However, very few 
Table 14. Summary of fusions 
Hybri­
dization 
Fusion Cell rate 
number type Specificity (%) 
NS-1 BIO.BR anti- 43 
C57BL/10Sn 
(anti-H-2^) 
NS-1 C57BL/10Sn anti- 47 
BIO.BR 
(anti-H-2k) 
NS-1 C57BL/10Sn anti- 34 
B10.D2 
(anti-H-2^) 
Sp-2/0 C57BL/10Sn anti- 65 
B10.D2 
(antl-H-2d) 
Sp-2/0 C57BL/10Sn anti- 15 
BIO.BR 
(anti-H-2k) 
Sp-2/0 C57BL/10Sn anti- 0 
BIO.BR 
fantl-H-2k) 
^Positive clones after first screening. 
^Cytotoxicity test. 
No. of Ascites Fusion 
positive producing length Screening 
clones^ clones (No.) (days) method 
2 2H1-5B (1) 99 CTX^ 
2 9A2-D2 (1) 76 CTX 
3 - 5 5  C T X  
2 - 6 3  C T X  
- - 17 CTX 
CTX 
Table 14. Continued 
Fusion 
number 
Cell 
type Specificity 
Hybri­
dization 
rate 
(%) 
No. of 
positive 
clones® 
Ascites 
producing 
clones (No.) 
Fusion 
length 
(days) 
Screening 
me thod 
7 NS-1 C57BL/10Sn anti-
BIO.BR 
(anti-H-2k) 
26 2« - 33 IIF^ 
8 NS-1 BALB/c anti-
BALB.K 
(anti-H-2^) 
78 5® 40 MCTX^ 
9 NS-1 BALB/c anti-
BALB.K 
(anti-H-2^) 
76 6 10E3-C12 
5D2-B10 
90 MCTX 
10 NS-1 BALB/C anti-
BALB.B 
(anti-H-2b) 
0 
11 NS-1 BALB/c anti-
BALB.B 
(anti-H-2^) 
70 1 MCTX 
^Lost (stopped growing). 
^Indirect immunofluorescence. 
®Contamina ted. 
%icrocy to toxicity test. 
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positive clones were found. This was due to problems in selecting a 
good screening method (discussed below), so with the best of methods 
only a limited number of wells could be analyzed. 
3) Another problem encountered was the stability of the clones. 
A large number of clones were lost in the process. Some stopped growing 
and died; others ceased to produce antibody probably due to chrcmosomal 
loss. 
4) All fusions directed to produce anti-H-2^ antibodies were un-
sucessful. In this case, it is very likely that the antibodies were 
absorbed from the ascites by the hybridomas themselves since NS-1 
cells express H-2*^. 
5) One fusion could take up to 6 months from the time of im­
munization of the mice. The maintenance of asceptic conditions was 
critical and difficult. Therefore, sançles of every positive well 
were always frozen and stored in liquid nitrogen during the process. 
We were successful in maintaining sterile conditions for more than 
two years. Only in the case of fusion 8 did we encounter problems 
of contamination. This occurred at a critical step and unfortunately, 
the fusion had to be terminated. 
6) Higher hybridization rates were obtained using hanologous 
spleen cells obtained from BALB/c mice (fusions 8, 9, and 11). Also, 
the production of ascites-producing tumors was enhanced by the use of 
BALB/c mice as donors for fusions and for recipients of hybridomas. 
Detailed flow diagrams of all fusions are shown in Figures 10 to 19. 
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2. Screening methods 
The first method used to screen antibody producing clones was a 
one-step cytotoxicity test (described in the Materials section). The 
test had technical limitations that allowed the screening of only a few 
clones. Also, this method detects only cytotoxic antibodies. However, 
since this was a quantitative test, it was used for titrations of ascites 
fluid. 
The indirect immunofluorescence test was developed to detect 
noncytotoxic antibodies. The use of L-929 cells facilitated the fixa­
tion of the cells. Lymphocytes were also used as target cells to 
confirm the presence of antibodies (Figures 20 and 21). The technique 
had some limitations. First, the volume of supernatant needed was very 
large (0.2 ml). Thus, all the screened cells had to be transferred first 
to 24 well plates, which consumed a large amount of medium. Second, as 
with the cytotoxicity test, the number of screened cells was limited. 
This last point must be emphasized since there were only 2-3 days to 
screen all the wells. Neither of the above two techniques could 
satisfy the time limits of the hybridoma production. 
The last method developed was a two-step microcytotoxicity test. 
This method proved to be very sensitive and could be done quantitatively, 
if necessary, although it was too time-consuming to do this when screening 
wells. The test enabled us to screen from 4 to 5 times the number of 
clones screened by the other two methods. It used a smaller amount 
of guinea pig serum (5 pi) and wells could be screened in a relatively 
short time. 
Noncytotoxic antibodies were screened by adding rabbit antimouse 
Figures 20 and 21. BIO,BR lymphocytes labeled with anti-H-2 
monoclonal antibodies (9A2D2). (Top figure; 
normal light; lower figure; ultraviolet light) 
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IgG. Using this procedure, one clone was detected in fusion 9 which 
did not produce cytotoxic antibody. This clone, however, failed to 
produce tumors when injected into mice. 
3, Production of ascites tumors 
Only a small number of clones produced tumors. Most of the tumors 
were solid so that only a small amount of each ascites could be ob­
tained (0.5-1 ml). Titers ranged from 1:20 to 1:250. 
The ascites were obtained when homozygous BALB/c mice were used 
as recipients. We were less successful when hybrids were used as 
recipients. In this case, up to 90% of the mice produced hard tumors 
with no ascites fluid. The optimal conditions for the production of 
ascites can be summarized as follows: 
a) Recipient mice should be BALB/c and older than 4 months of 
age. 
b) Mice should be injected with the cells at least 7 days after 
pristane injection. 
c) No less than 4 x 10^ cells and no more than 10^ cells should 
be injected into a mouse (all in a 0.1 to 0.2 ml volume). 
d) Positive ascites were obtained usually between 2 and 3 weeks 
after cell injection. Tumors appearing after 5 weeks of injection were 
always negative for antibody production. 
e) Ascites should be collected approximately between 3 and 5 days 
after subcutaneous tumors are palpable. Mice should be checked daily 
to prevent the death of the animal before the ascites is collected. 
94 
4. Purification of monoclonal antibodies 
a. Protein A sepharose purification Two typical elution 
profiles of two monoclonal antibodies (2H1-5B anti H-2^ and 9A2-D2 anti 
H-2 ) are shown in Figures 22 and 23, respectively. 
In both elutions, the fractions of the second peak (fractions 9-13 
in Figure 22 and fractions 11-15 in Figure 23) were tested against rabbit 
anti-mouse IgG for confirmation. Positive reactions were obtained only 
with the fractions included in the second peak. In the first purification 
(Figure 22), the supernatant was concentrated 10 times and the final 
concentration after purification was 76 tig/ml (7.6 ng/ml in the original 
supernatant). In Figure 23, the supernatant was concentrated 40 times 
and the final concentration was 240 ng/ml (6 (Jg/ml in the original 
supernatant). 
In both purifications, most of the antibody was eluted in one 
fraction. The problem encountered with this procedure was that the 
purified antibody apparently lost its complement-binding activity 
so that it was no longer cytotoxic in a direct cytotoxicity test. 
b. Ammonium sulphate precipitation Monoclonal antibodies 
were precipitated from ascites fluid using 50% saturation. Up to 2 mg/ml 
of antibody was purified. As expected, the antibody was of the same class 
and subclass found in the original supernatant. Although some of the 
cytotoxicity was still conserved, the titer was lower than the original 
ascites. Since the ascites was not nonspecifically cytotoxic for lympho­
cytes or to embryos (at high dilutions, see below), the unpurified 
ascites was used for embryo experiments. 
Figure "22. Elution profile of protein A sepharose purification of 
2H1-5B monoclonal antibody. (Final concentration after 
purification was 76 Mg/ml of protein) 
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Figure 23. Elution profile of protein A sepharose purification of 
9A2-D2 monoclonal antibody. (Final concentration after 
purification was 240 pg/ml) 
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5. Analysis of monoclonals 
a. Control ascites Control ascites, obtained by injecting 
NS-1 cells into BALB/c mice, was tested against lymphocytes of 3 
different haplotypes with no effect (Table 15). The cytotoxicity of 
the control ascites was also tested against embryos (see below). 
Table 15. Testing of control ascites against lymphocytes. Figures 
show percent killing of lymphocytes 
Ascites Hap lo type 
dilution H-2d H-2b a-2k 
1:10 < 5 < 5 7 
1:20 < 5 < 5 < 5 
1:50 10 < 5 < 5 
1:100 < 5 8 10 
b. Isotype analyses of monoclonal antibodies Monoclonal anti­
bodies obtained in ascites form are summarized in Table 16. The iso­
type of antibody is shown in the table. All antibodies produced only 
one precipitation line with the respective antiserum and none with the 
rest of the antisera. 
c. Titration of monoclonal antibodies The titration curves 
(direct cytotoxicity) of all 5 monoclonal antibodies against spleen 
t] 
lymphocytes are shown in Figures 24-28 . From the figures, it can be 
observed that antibodies 11-4.1 and D52-B10 are the ones found in the 
highest concentration. This last observation is important since it 
will be reflected in our results with embryos (see below). All of the 
^The target lymphocytes used were: C57BL/10Sn (H-2^) for Figure 24 
and BIO.BR for Figures 25-28. 
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Table 16. Isotypes of monoclonal antibodies 
McAb Specificity Isotype 
2H1-5B anti-H-2^ IgG2b 
9A2-D2 anti-H-2^ IgG2a 
5D2-B10 anti-H-2^ IgG2b 
10E3-C12 anti-H-2^ IgG2a 
11-4.1 anti-H-2^ IgG2a 
monoclonals showed much higher titers than conventional antisera. How­
ever, some of them showed a lower titer than expected. This might be 
attributable to their hard-tumor origin, instead of soft-tumor origin. 
d. Specificity of monoclonal antibodies Monoclonal antibodies 
were tested against a panel of 8 haplotypes (Table 17). Monoclonal 
antibody 2H1-5B reacted only with the H-2^ haplotype. On the other 
hand, monoclonals 9A2-D2, 5D2-B10 and 10E3-C12 reacted with both a and k 
haplotypes indicating that they were all directed against the H-2K 
subregion. The fifth monoclonal, 11-4.1, reacted against several 
haplotypes. This antibody was originally produced using inbred strains 
(CKB lymphocytes into BALB/c recipients) and not congenic mice. This 
could account for the extensive cross reactivity. 
The theoretical specificities towards which these antibodies could 
be directed are shown in Table 18. All monoclonals except 11-4.1 could 
be directed to either a private or a public specificity. On the other 
hand, 11-4.1 is directed only to a public specificity. 
Figure 24. Titration curve for 2H1-5B monoclonal antibodies 
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Figure 25. Titration curve for 9A2-D2 monoclonal antibodies 
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Figure 26. Titration curve for 5D2-B10 monoclonal antibodies 
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Figure 27. Titration curve for 10E3-C12 monoclonal antibodies 
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Figure 28. Titration curve for 11-4.1 monoclonal antibodies 
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Table 17. Specificity of monoclonal antibodies. (All ascites were 
tested at a 1:10 dilution using a direct cytotoxicity 
test. Clones showing above 30% cytotocicity were con­
sidered positive) 
Clone 
Haplotype 2H1-5B 9A2D2 5D2-B10 10E3-C12 11-4.1 
k - + + + + 
a 
- + + + + 
b + - - -
-
q - - - - + 
d - - - - -
r - - - - + 
s - - - - -
u . - - - - -
Table 18. Theoretical and probable specificities to which the mono­
clonal antibodies could be directed. (Private specificities 
are underlined.) (From Demant's 1979 haplotype table) 
Clone Theoretical specificities Probable specificities^ 
2H1-5B 28, 
2, 
33, 35, 36, 39, 53, 
6, 27, 28, 29, 56 
54 33, 
2 
39 
9A2-D2 
5D2-B10 
10E3-C12 
S 1, 1, 3, 8, 11, 23, 24, 25 3, 5, 32 , 45, 49, 52 23, 24, 25 
11-4.1 1, 
1, 
3, 5, 8, 11, 23, 24, 
3, 5, 32 
25, 45, 49, 52 1, 3, 5, 45, 49 
^Probable specificities were determined by elimination, using data 
from Table 17 and Demant's (1979) table. 
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C. Detection of H-2 Antigens on Preimplantation Embryos 
1. Indirect immunofluorescence 
Embryos from C57BR/cdj (H-2 ) females were collected at 89 hours 
and 113 hours post hCG and used in this part of the project. Labeling 
of embryos using this technique was not pursued further because of the 
multiple problems encountered (see below). Also, a new technique (see 
below) was developed in our laboratory that is potentially much more 
sensitive than immunofluorescence. More than 10 embryos were used in 
two different experiments, none of which were labeled. 
The major problems encountered with the indirect immunofluorescence 
technique were the following: 
1. Labeling was very weak and it was very difficult to determine 
with objectivity if the embryos were indeed labeled. 
2. Embryos with the zona pellucida intact were labeled non-
specifically. 
3. Some embryos were lost after pronase treatment to remove the 
zona pellucida. This is a big disadvantage when working with inbred 
embryos which are very difficult to obtain. 
4. Finally, the assay used a relatively large amount of ascites 
which is scarce. 
2. DNA synthesis assay 
a. Screening of guinea pig complement Commercially available 
guinea pig serum (GIBCO) was used as a source of complement and screened 
against CFl embryos to measure nonspecific cytotoxic effects. As can 
be observed from Table 19, this complement was highly cytotoxic for both 
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Table 19. Screening of guinea pig complement. (Numbers represent 
7o inhibition of DM synthesis of controls (no complement)) 
Commercial Fresh 
G.P.C. G.P.C. 
Morulas 66 42 
Blastocyst 53 31 
morulas and blastocysts. Fresh guinea pig serum was shown to be less 
cytotoxic for both stages of embryonic development (Table 19). 
b. Titration of ascites using embryos A titration curve for 
the control ascites was necessary because of the nonspecific cytotoxic 
effects that the ascites fluid has on embryos. 
The titration curve (Figure 29) was done with A/J mice and the 
5D2-B10 monoclonal ascites. This strain was chosen because of its 
relatively high yield of embryos. As can be observed from Figure 29, 
nonspecific cytotoxic effects decreased almost completely at a 1:20 
dilution. On the other hand, the specific 5D2-B10 ascites shows 
optimal cytotoxicity at this dilution. While the 5D2-B10 ascites shows 
a typical titration curve, the control ascites shows high nonspecific 
effects which are quickly eliminated by dilution. The largest dif­
ference observed between both ascites was at a 1:20 dilution. Thus, 
this dilution was subsequently used to test the rest of the mono-
clonals (see Table 21). Since A/J mice gave the largest amount of 
embryos, they were tested against the rest of the monoclonals using 
three dilutions (Table 20). It can be observed that none of the rest 
of the monoclonals reacted significantly with the embryos. Embryos of 
Figure 29. Titration curves for control (•) and D52-B10 (o) ascites 
using A/J embryos 
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Table 20. Detection of H-2 antigens on A/J embryos with monoclonal 
antibodies. (Numbers represent 7» inhibition of DNA. 
synthesis + standard error of the mean.) (Raw data are 
shown in Tables 61 and 62, Appendix B) 
Dilution of ascites 
Clone 1:20 1:50 1:100 
11-4.1 2 + 7 21 ± 10 0 + 0 
9A2-D2 1 ± 2 0 + 1 6  n . d .  
10E3-C12 7 ± 0 0 ± 0 0 + 0 
5D2-B10 55 ± 13 1 8 + 4  8 + 2  
Table 21. Inhibition of DNA synthesis (+ S.E.) in embryos after being 
treated with monoclonal ascites at a 1:20 dilution. (Raw 
data are shown in Tables 63, 64, and 65, Appendix B) 
Strain 
Clone 
CBA 
(H-2h 
C57BR/cdj 
C^k) 
C57BL/6 
(H-2b) 
11-4.1 49 ± 6* 0 + 25 -
9A2-D2 0 + 14 2 + 35 — 
5D2-B10 31 + 3** 2 + 4  -
10E3-C12 n.d. 57 + 16 — 
2H1-5B — - 0 + 14 
^Statistically different from 0% inhibition of DM synthesis 
(controls) (p <0.005). 
^^Statistically different from 0% inhibition of DNA. synthesis 
(controls) (p <0.05). 
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three more strains were used with our monoclonals using a 1:20 dilution. 
Monoclonal antibody 11-4.1 reacted significantly with CBA embryos 
(Table 21) while monoclonal 5D2-B10 which already was shown to react 
with A/J mice (Figure 31) also reacted with CBA mice (Table 21). The 
rest of the strains did not show any effect from the treatment with the . 
monoclonals. It is of interest that both these antibodies (11-4.1 and 
D52-B10) showed the highest titer (Figures 26 and 28). 
3. Indirect cytotoxicity assay for embryos 
a. Titration of antiserum with thymocytes Before the indirect 
test was tried on embryos, a pilot study was done on thymocytes. The 
mouse allo-antisera for the following studies was prepared as described 
earlier by immunizing A/J female mice with DBA/2 splenocytes. The 
DBA/2 strain was chosen because of the availability of a relatively 
large number of embryos of this strain. 
Both the direct (mouse anti-mouse) and indirect (rabbit anti-
mouse) antibodies were titrated in a block experiment using DBA/2 
thymocytes (see Table 22). Dilutions ranging from 1:4 to 1:64 were 
used of both antibodies hoping to find the optimal concentration of 
each. As expected, thymocytes did not react spontaneously with the 
rabbit anti-mouse Ig antibody, since they lack Ig on their surface. 
The results of the block titration are shown in Table 22. Using a 
second antibody, we were able to obtain cytotoxicity levels up to 66%. 
The low cytotoxicity levels of the mouse alloantisera are due to the 
relatively low concentrations of H-2 antigens on thymocytes, when 
compared to B cells. Thus, the indirect cytotoxicity test allows 
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Table 22. Block titration of direct (mouse anti-mouse) and indirect 
(rabbit anti-mouse) Ig antibodies using thymocytes, 
(Numbers represent % inhibition of DNA synthesis + S.E.) 
Rabbit 
anti-mouse Mouse anti-mouse dilution 
(dilution) 1:4 1:8 1:16 1:32 1:64 
— 
< 3® 28 + 2 19 + 5 25 + 3 < 3 < 3 
1:4 <3 26 ± 3 3 6 + 7  26 + 4 49 ± 5 61 + 2 
1:8 < 3 32 + 3 33 + 3 60 + 4 65 + 3 66 + 1 
1:16 < 3 32 + 2 20 + 5 34 + 9 19 + 1 45 + 1 
1:32 < 3 33 ± 1 20 + 2 1 4 + 1  28 + 7 2 2 + 2  
1:64 < 3 24 + 4 17 + 1 < 3 < 3 17 + 2 
^Percent cytotoxicity of thymocytes. 
direct antibody dilutions to be used as high as 1:64. This is im­
portant because one of the goals of developing the test was to 
eliminate nonspecific cytotoxic effects of the serum on embryos by 
using high dilutions of antiserum. 
b. Titration of the antibodies using embryos The dilu­
tions of antisera cytotoxic for thymocytes were not toxic for 
embryos. Thus, a similar kind of block experiment was performed using 
embryos. To find the optimal concentration of direct and indirect 
antibodies, a large number of experiments was necessary to complete the 
table, since even with DBA/2 mice, the availability of embryos is 
limited. Similar conditions were maintained in all experiments (same 
time, same source of both antibodies and conçlement). 
As can be observed from Table 23, the mouse alloantisera by 
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Table 23. Indirect cytotoxicity test with DBA/2 embryos. (Numbers 
represent % inhibition of DNA. synthesis + S.E. Mouse 
anti-mouse serum used was A/J anti DBA/2. Embryos were 
collected 89 hours post hCG injection) 
Rabbit 
anti-mouse , 
Mouse anti-mouse dilution 
18 
dilution 1:4 1:8 1:16 1:32 1: 64 
- 0^ 65 ± 5 45 ± 12 0 + 4 5 + 5 13 If
 
o
 
1:4 o
 
1+
 
25 40 + 9 4 0 + 0  5 + 4 0 + 0 0 ± 2 
1:8 13 ± 9 72 ± 2 5 1 + 8  3 + 9 10 ± 4 12 ± 6 
1:16 0 + 2 79 ± 17 27 + 13 17 + 9 0 + 0 0 ± 2 
1:32 0 + 6 63 ± 1 24 + 11 45 + 9 15 + 16 25 ± 15 
1:64 n.d. 47 ± 0 2 6 + 7  0 + 7 0 + 1 0 ± 2 
itself was cytotoxic up to a 1:8 dilution. 
The addition of the second antibody unfortunately did not seem 
to augment the inhibition of DNA synthesis. There was only one point 
in which magnification of the inhibition was observed (1:16 mouse anti-
mouse and 1:32 rabbit anti-mouse). In this particular point, the experi­
ment was repeated twice independently. However, it is still not clear 
if this is a real effect. These apparently negative results probably 
reflect differences in antigenic expression of embryos compared to the 
thymocytes. 
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IV. DISCUSSION 
In this work, we show for the first time that genes associated with 
the H-2 complex influence early embryonic development. The approach 
taken to study development was through observation of timing events. 
The availability of highly inbred strains and congenic strains made 
possible the association of these timing events with the extensively 
studied H-2 complex. 
To study timing events, we took the most direct approach which is 
the observation of the number of cells (or cell divisions) at different 
times during development and made comparisons among strains. Counting 
of the cells was done using the Tarkowski method which proved to be 
accurate and reliable (Figures 1 and 2 and Table 2). 
The first proof of association between H-2 genes and development 
was observed after comparing embryos from different inbred strains 
expressing independent haplotypes (Tables 3 and 4). Consistently, only 
H-2 strains had embryos with fewer cells at both stages of develop­
ment (68 and 89 hours post hCG). Confirmation of association of H-2 
and timing of development was obtained using congenic mice. From the 
data presented in Table 5 and Figures 3 and 4, it is clear that by 
changing the genetic composition of a mouse only at the H-2 complex, 
its development changes from "fast" to "slow" and vice versa. The 
gene(s) responsible for this effect was named Fed for preimplantation 
embryo development. The rest of this study was dedicated to the 
characterization of the Fed gene. First, we focused on finding the 
earliest time of expression of the gene(s). It was shown that the Fed 
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gene(s) does not show expression at the time of ovulation, but it does 
influence the time of the first cleavage division (Figures 5 and 6). 
It could be argued that time of fertilization influences these changes. 
However, it has been shown (Esworthy, 1979) that even if the ova from 
these strains are fertilized synchronously vitro, the differences in 
cell number per embryo seen at 89 hours post hCG are maintained. Thus, 
the Fed gene(s) effect has to be expressed after fertilization. 
The Fed gene(s) was also shown to influence not only the timing 
of the first cleavage division, but also the subsequent rate of develop­
ment (Figure 7). These last observations are in disagreement with the 
experiments done by McLaren and Bowman (1973), in which no differences 
in rate of development among strains were found. Nevertheless, compari­
sons between these two studies are difficult to make since these authors 
did not use the same strains or the same time points. In an effort to 
explain the wide differences among strains, a theoretical curve was 
drawn (Figure 8). We can see that at 65 or 89 hours, differences in 
timing between fast and slow strains are maximal. One can also observe 
that the gap between "slow" and "fast" strains widens with time and 
could theoretically change the time of implantation and the length of 
the gestation period. Differences in gestation periods and implantation 
times could have important implications. We will return to these points 
later in the discussion. 
The next step in this study was characterizing the Fed gene(s) 
through classical genetic analysis. This proved to be a difficult 
task since cleavage divisions are a complex event subject to non-H-2 
genetic influence as well as environmental effects. The analysis showed 
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that the Ped gene is dominant and not subject to maternal effects 
(Table 7). The segregation of the genes follows a consistent pattern 
showing maximum variability at the generation (Figure 9). The back-
crosses showed different distributions being "slower" when crossed 
against the "slow" development parental strain and faster when crossed 
against the "fast" developmental parental strain (Figure 9). It is 
difficult to draw more conclusions fr(m these data since we are dealing 
with a continuous trait (cell No./embryo) and segregation is not clear-
cut. Also, we did not simultaneously determine the H-2 type of the embryos 
the cell No./embryo. This would be a formal test of linkage of the Ped 
gene to the H-2 complex. (This will be discussed further later on.) 
Nevertheless, it is clear that there is a major H-2 linked gene which 
affects rate of development, but background genes are involved too. 
The background effect was already evident in the first cleavage divi­
sion studies. In these experiments, the BIO.BR mice showed an inter­
mediate time of cleavage between its background strain (C57BL/10Sn) 
and its H-2 donor strain (C57BR/cdj) (Figure 6). 
Background gene effects became more apparent in studies using 
BALB/c congenic mice. All the strains with BALB/c background showed 
slow development regardless of their H-2 haplotype (Table 12). 
It is logical to assume that if the slow Ped gene(s) is indeed 
H-2 linked, it could be associated with other haplotypes besides H-2^. 
From all the haplotypes screened (Tables 10 and 11), only the H-2^ 
(BIO.RIII) was found to express the slow Ped allele. This may not be 
Ic r 
surprising since H-2 and H-2 haplotypes are very similar (Figure 30). 
One other aspect that we looked into was the possibility of gene 
123 
ANTIGENIC SPECIFICITIES 
H-2^ 13 5 7 8 11 23 24 25 32 45 47 49 52 
H-2^ 1 3 5 6 8 11 18^ 25 28 45 47 49 52 
^Second private specificity is undetermined. 
Ic y y 
Figure 30. Comparison of H-2 and H-2 haplotypes (Demant, 1979). 
(Private specificities are underlined.) 
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complementation. Gene complementation is a phenomenon previously ob­
served in H-2 associated traits, such as the immune response to small 
polypeptides (Benacerraf and Germain, 1978). We did not see any evidence 
of gene ccmplementation when two "slow" strains were crossed (Table 13). 
The only evidence of possible gene interaction comes from the BALB.K 
data shown in Table 12 (89 hours post hCG). The BALB.K mice were shown to 
be significantly slower than the BÀLB.B and BALB/c strains, raising 
the possibility of interaction between H-2 and background genes. 
This kind of background complementation between genes on different 
chromosomes has been shown in other systems in the mouse, as the 
expression of the enzyme P-galactosidase (Palgen, 1979). 
At this point, a question that should be raised is whether it is 
certain that the Fed gene(s) is linked to the H.-2 complex. According 
to Amos (1981), due to the limited number of backcross generations 
involved in producing congenic lines, a segment of the chromosomes up 
to 13 centimorgans (cm) long can be included in the congenic line. 
The T/t complex, which has been proven to influence development (Bennet, 
1975), is only 13.5 cm to the centromeric side of the H-2 complex 
(Vitteta and Capra, 1978). Thus, although unlikely, it could be argued 
that some of the Fed gene effects could be influenced by the T/t complex. 
One argument against this is that the slow Fed allele of H-2 seems to 
map to the D end of the H-2 complex (Tables 10 and 11) which is at the 
opposite end of the H-2 complex than the T/t complex. One way to solve 
this problem would be to use an enzymatic marker like glyoxylase (Glo) 
which maps between the H-2 fand T/t complexes (Green, 1981). It has been 
shown that C57BL/10Sn and BIO.BR strains express the same (common) Glo 
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isozyme (îdeo et al., 1977). If the C57BR/cdj strain could be shown 
to express the variant isozyme, it would seem highly probable (barring 
a double cross over event) that only the H-2 complex and not the T/t 
complex is included in the BIO.BR congenic strain. These studies are 
currently in progress in our laboratory. Alternatively, if C57BR/cdj 
mice express the common isozyme, classical segregation studies would 
have to be performed in which H-2 haplotype and cell number were 
determined simultaneously to prove linkage of H-2 haplotype and slow 
development. 
The next step taken in this study was to search for the Fed 
gene product. The simplest theory would be to assume that the Fed 
gene products are the H-2 antigens themselves. Due to their specificity, 
monoclonal antibodies were produced against H-2 antigens, hoping to 
show the presence of H-2 antigens on the surface of embryos. Here, 
we have to stop and dedicate a section of this discussion to the 
production of monoclonal antibodies since we think there is room for 
improvement. These are some of the improvements that can be done to 
our technique: 
Immunizations should always be done with BALB/c mice as recipients 
since production of ascites in BALB/c mice is much easier than in 
hybrids. It is not necessary to use congenic mice for immunization. 
A more crude antigen, like splenocytes from inbred strains of different 
haplotypes, could work better. This is possible since one of the ad­
vantages of the hybridoma technology is the ability of obtaining a 
specific antibody from a crude antigen. 
The key step in monoclonal antibody production is the screening 
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procedure. Our procedures presented problems in sensitivity and the 
number of wells that could be screened. Efforts should be concentrated 
in finding a fast and reliable method in which literally hundreds of 
wells can be screened in one or two days. Such a method may be the 
one recently described by Lansdorp et al. (1980) in which wells are 
screened using an immunoperoxidase method. The expansion process might 
be improved by pristane priming of BALB/c mice months before cell in­
jection. (Priming with pristane could be done the day of the fusion.) 
Older mice (5 months or more) should be used as recipients. 
In spite of these problems, in general, our procedure worked very 
well. Hybridization rates were high for most of the fusions (Table 14). 
Also, we were able to maintain fusions going for more than two years 
without any serious incidences of contamination. The fusion protocol 
has been completely worked out (see Appendix C), and so are other im­
portant steps of the hybridoma production like cell growth, cloning 
and storage. With the screening problem solved, this could be a very 
efficient system in the production of monoclonal antibodies. We were 
able to obtain some monoclonal ascites (Tables 16 and 18) to be used on 
embryos. The ascites were used in an embryo assay recently developed 
in our laboratory (Cozad et al., 1981). In this way, we confirmed 
previous studies done in our laboratory (Cozad and Warner, 1981) and 
other laboratories (Searle et al., 1976; Webb et al., 1977) showing 
the presence of H-2 antigens on embryos (Tables 20 and 21; Figure 29). 
Moreover, our studies with monoclonal antibodies suggest that embryos 
of the same haplotype do not necessarily have the same expression of 
H-2 antigens. Thus, it was shown that monoclonal ascites 11-4.1 (anti-
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H-2K^) reacted only with CBA embryos, while it killed adult cells 
of the CBA, A/J and C57BR/cdj strains (Tables 17, 20 and 21). On the 
other hand, monoclonal ascites 502-B10 reacted with both CBA and A/J 
embryos but not with C57BR/cdj embryos. It seems very likely that 
these two monoclonals were the only ones to show embryo reactivity be­
cause they had the highest titers (Figures 27 and 28) and their effect 
was not marked by the nonspecific cytotoxicity of the ascites fluid 
(see Figure 29). More evidence of differences in antigenic expression 
between adult cells and embryos was obtained with the indirect cytotoxicity 
assays. The adult and embryonic cytotoxicity block experiments differ 
dramatically (Tables 22 and 23). In this series of experiments, using 
adult thymocytes, there was an increase in killing observed at several 
of the dilutions when the second antibody was used (Table 22). On the 
other hand, in the embryo experiments, we only saw an increase at one 
dilution combination (1:16 mouse anti-mouse, 1:32 rabbit anti-mouse Ig, 
see Table 23). In light of the results with thymocytes, it is hard to 
assess if our only positive observation with embryos is real or just 
an artifact. However, it is clear again that there are differences in 
antigenic distribution between embryos and adult spleen cells. 
The finding that H-2 antigens are expressed on early embryos is 
important for our studies. As we mentioned earlier in this discussion, 
H-2 antigens could be used to type the embryos obtained in a backcross 
and see if they indeed follow the theoretical distribution; this would 
be considered a formal proof of linkage of the Fed gene to the H-2 
complex, as mentioned previously. 
The presence of H-2 antigens is also important because they could 
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be the Ped gene products themselves. The idea that H-2 cell surface 
products control rate of development is an attractive one. We know 
that cell contact may play an important role in differentiation and cell 
commitment early in ontogeny. H-2 products have been shown to be im­
portant in a variety of cell recognition events (i.e., T^ell'^cell 
interaction in the immune response; Klein, 1979). The Ped gene could 
similarly control cell-cell interaction in developing embryos. Thus, 
the Ped gene expression could be just one more of the multiple pleiotropic 
effects controlled by a small number of polypeptides encoded by the H-2 
complex (Klein et al., 1981). On the other hand, if the Ped gene product 
is a unique protein, it will follow Janeway's (1981) observations 
which suggest that there is an adequate number of genes in the H-2 
complex to code for all the different traits associated with the complex. 
In this case, the Ped gene will be added to the already long list of 
traits (over 60) associated with the H-2 complex (Klein, 1978). 
The results presented in this thesis could have some long-range 
practical applications. We already mentioned that differences in rate 
of cleavage could also mean differences in implantation time and/or 
differences in length of gestation. Timing is important in the implanta­
tion process, since apparently, the mother is in a suppressed im­
munological state exactly at the time of implantation (Clark and 
McDermott, 1981). Thus, it would be interesting to determine the 
time of implantation for strains expressing the "fast" and "slow" alleles. 
As far as length of gestation, there are already some reported 
similarities between the patterns of development described for the mice 
in this work and development in humans. It is accepted that normally 
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developed babies can have gestation periods of different lengths (from 
7 to 10 months) and that this could be genetically determined (Annis, 
1979). We have not measured length of gestation in the mice with dif­
ferent Ped alleles; this would be an interesting experiment. A better 
understanding of the genetics of gestation is of importance in clinical 
embryology. For instance, the prognosis for a small child born after 
a "normal" length gestation and an equally small child born after an 
abnormally short gestation may be very different. Leaving the uterus 
early is not in itself deleterious if the baby is a short-gestation 
baby. On the other hand, growing less than normally during a full 
period implies pathology of fetus, placenta or mother. 
The observation that H-2 antigens can be involved in development 
could also be related to human studies. There is now a large amount of 
evidence showing that HLA could be related to development. Certain HLA 
antigens have been found with higher frequencies in patients suffering 
from pathological pregnancies (Gerencer et al., 1979), repeated abortions 
(Komlos et al., 1977), and severe pre-eclampsia (Redman et al., 1978). 
(Pre-eclampsia is a toxemia of late pregnancy characterized by hyper­
tension, protenuria and edema. It can lead to the acute phase of the 
disease called eclampsia, which can be fatal for both the baby and 
the mother.) 
The study of timing in early development could have multiple 
practical applications. For example, in the recent experiments where 
human pregnancies were established using embryos fertilized and grown 
in vitro (Edwards et al., 1980; Lopata et al., 1980) timing was a key 
factor in determining that the embryos were ready to be transferred back 
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to the pseudopregnant mother (Steptoe et al., 1980). The precise 
knowledge of how timing is controlled could be of value in fertility vs. 
infertility studies and in studies of abnormal fetal development. This 
knowledge, no doubt, will be most useful in the pursuit of an effective, 
safe and reliable contraceptive method. For instance, a pregnancy "vac­
cine" could be produced using monoclonal antibodies reacting only with 
stage specific antigens on early embryos but not with adult tissues. 
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Table 24. CFl data (65 hours post hCG) 
Cell number/ 
Expt. No. Observation No. embryo 
1 7 
2 8 
3 3 
4 5 
5 8 
6 7 
7 6 
8 7 
9 4 
10 8 
11 8 
12 8 
13 4 
14 5 
15 8 
16 8 
17 8 
18 4 
19 8 
20 7 
21 7 
22 8 
23 8 
24 5 
25 8 
26 7 
27 8 
28 6 
29 8 
30 4 
31 4 
32 7 
33 8 
34 8 
35 5 
36 6 
37 6 
38 8 
39 7 
40 7 
Table 24. Continued 
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Cell number/ 
Expt. No. Observation No. embryo 
41 8 
42 6 
43 7 
44 8 
45 8 
46 6 
47 6 
48 8 
49 5 
50 8 
Totals 4 50 6.8 (1.0) 
146 
Table 25. CFl data (89 hours post hCG) 
Cell number/ 
Expt. No. Observation No. embryo 
1 55 
2 32 
3 65 
4 46 
5 48 
6 66 
7 53 
8 54 
9 45 
10 52 
11 22 
12 16 
13 21 
14 18 
15 23 
16 29 
17 33 
18 19 
19 28 
20 48 
21 63 
22 36 
23 64 
24 51 
25 42 
26 61 
27 41 
28 50 
29 64 
30 64 
31 16 
32 39 
33 67 
34 30 
35 47 
36 37 
37 62 
38 51 
39 33 
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Table 25. Continued 
Cell number/ 
Expt. No. Observation No. embryo 
40 70 
41 57 
42 42 
43 34 
44 53 
45 68 
46 46 
47 45 
48 37 
49 47 
50 64 
51 35 
Totals 5 51 44.4 (2.2) 
Table 26. Raw data for Figure 7 
Hours Replication 
Observation Strain® post hCG (No. expt.) 
1 C57 
2 C57 
3 BIO 
4 CBR 
5 C57 
6 C57 
7 C57 
8 BIO 
9 BIO 
10 CBR 
11 C57 
12 C57 
13 BIO 
14 BIO 
15 CBR 
16 C57 
17 C57 
18 C57 
19 BIO 
20 BIO 
21 CBR 
22 CBR 
23 C57 
24 C57 
25 C57 
26 C57 
47 1 
47 2 
47 1 
47 1 
53 1 
53 2 
53 3 
53 1 
53 2 
53 1 
56 1 
56 2 
56 1 
56 2 
56 1 
65 1 
65 2 
65 3 
65 1 
65 2 
65 1 
65 2 
89 1 
89 2 
89 3 
89 4 
*C57 = C57BL/10Sn; BIO = BIO.BR; CBR = C57BR/cdj 
Cell Log2 cell 
Embryos Mice number/ number 
scored used embryo embryo 
39 5 1.9 0.93 
30 5 2.1 1.07 
58 9 2.2 1.14 
26 4 1.8 0.9 
32 10 3.0 1.6 
3 1 4.0 2 
19 4 2.9 1.5 
29 6 2.9 1.5 
56 6 3.4 1.8 
32 4 2.3 1.2 
18 7 4.2 2 
22 5 3.6 1.8 
22 4 3.4 1.8 
41 5 3.8 1.9 
36 5 3.0 1.6 
7 1 7.0 2.8 
36 10 7.5 2.9 
20 4 8.2 3.0 
26 4 6.0 2.6 
33 8 6.2 2.6 
18 4 4.6 2.2 
26 8 4.8 2.3 
4 5 34.0 5.1 
3 1 37.0 5.2 
3 3 25.0 4.6 
4 6 39.0 5.3 
Table 26. Continued 
Observation Strain 
Hours 
post hCG 
Replication 
(No. expt.) 
Embryos 
scored 
Mice 
used 
Cell 
number/ 
embryo 
Log2 cell 
number 
embryo 
27 C57 89 5 11 17 28.6 4.9 
28 C57 89 6 12 10 37.8 5.3 
29 C57 89 7 6 15 29.3 4.9 
30 C57 89 8 5 11 33.0 5.0 
31 BIO 89 1 2 7 20.5 4.4 
32 BIO 89 2 4 3 24.7 4.6 
33 BIO 89 3 8 10 22.9 4.5 
34 BIO 89 4 7 9 26.4 4.7 
35 BIO 89 5 19 14 20.3 4.3 
36 BIO 89 6 10 13 24.4 4.6 
37 CBR 89 1 10 5 13.8 3.8 
38 CBR 89 2 45 6 19.8 4.3 
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Table 27. DBA/2 data (65 hours post hCG) 
Cell number/ 
No. expts. Observation No. embryo 
1 4 
2 4 
3 7 
4 7 
5 8 
6 7 
7 8 
8 5 
9 7 
10 7 
11 7 
12 4 
13 7 
14 7 
15 7 
16 7 
17 8 
18 8 
19 8 
20 8 
21 4 
22 7 
23 8 
24 8 
25 4 
26 6 
27 6 
28 4 
29 8 
30 4 
31 4 
32 4 
33 8 
34 8 
35 4 
36 7 
37 8 
38 7 
39 5 
40 6 
41 8 
42 13 
43 8 
Table 27. Continued 
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Cell number/ 
No. expts. Observation No. embryo 
44 7 
45 8 
46 4 
47 5 
48 6 
49 6 
50 8 
51 8 
52 8 
53 3 
54 3 
55 3 
56 9 
57 6 
58 8 
59 8 
60 8 
61 6 
62 5 
63 3 
64 3 
65 6 
66 6 
67 7 
68 8 
69 3 
70 3 
71 7 
72 6 
73 9 
74 6 
75 7 
76 6 
77 7 
78 8 
79 7 
80 7 
81 8 
82 9 
83 9 
84 3 
85 9 
86 6 
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Table 27. Continued 
Cell number/ 
No. expts. Observation No. embryo 
87 8 
88 8 
89 7 
90 7 
91 7 
Totals 1 91 6.9 (0.4) 
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Table 28. C3H/HeJ data (65 hours post hCG) 
Cell number/ 
No. expts. Observation No. embryo 
1 8 
2 7 
3 5 
4 7 
5 7 
6 7 
7 6 
8 6 
9 8 
10 6. 
11 5 
12 5 
13 5 
14 8 
15 7 
16 6 
17 7 
18 8 
19 5 
20 6 
21 7 
22 5 
23 6 
24 7 
25 6 
26 8 
27 6 
28 7 
29 7 
30 8 
31 7 
32 6 
33 8 
34 5 
35 8 
36 8 
37 6 
38 6 
39 6 
40 6 
41 8 
42 8 
43 6 
154 
Table 28. Continued 
Cell number/ 
No. expts. Observation No. embryo 
44 7 
45 7 
46 3 
47 3 
48 5 
Totals 1 48 6.4 (0.1) 
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Table 29. C57BR/cdj data (65 hours post hCG) 
Cell number/ 
No. expts. Observation No. embryo 
1 4 
2 4 
3 4 
4 4 
5 4 
6 4 
7 3 
8 3 
9 5 
10 3 
11 3 
12 4 
13 4 
14 4 
15 7 
16 7 
17 7 
18 6 
19 8 
20 8 
21 8 
22 8 
23 3 
24 4 
25 6 
26 4 
27 4 
28 8 
29 8 
30 7 
31 3 
32 4 
33 4 
34 4 
35 4 
36 4 
37 4 
38 4 
39 4 
40 4 
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Table 29. Continued 
Cell number/ 
No. expts. Observation No. embryo 
41 2 
42 3 
43 3 
44 4 
Totals 2 44 4.7 (0.3) 
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Table 30. DBA/2 data (89 hours post hCG) 
Cell number/ 
No. expts. Observation No. embryo 
1 44 
2 56 
3 32 
4 21 
5 18 
6 50 
7 41 
8 32 
9 22 
10 32 
11 27 
12 30 
13 16 
14 42 
15 40 
16 41 
17 27 
18 32 
19 45 
20 16 
21 16 
22 32 
23 51 
24 18 
25 27 
26 20 
27 32 
28 18 
29 18 
30 38 
31 32 
32 34 
33 34 
34 32 
35 30 
36 39 
37 22 
38 43 
39 29 
40 28 
41 26 
42 26 
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Table 30. Continued 
Cell number/ 
No. expts. Observation No. embryo 
43 28 
44 16 
45 36 
46 16 
47 52 
48 21 
49 30 
50 24 
51 28 
52 28 
53 26 
Totals 2 53 30.5 (1.4) 
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Table 31. C3H/HeJ data (89 hours post hCG) 
Cell nimber/ 
No. expts. Observation No. embryo 
1 20 
2 30 
3 24 
4 26 
5 23 
6 18 
7 38 
8 27 
9 27 
10 24 
11 27 
12 27 
13 29 
14 23 
15 23 
16 26 
17 26 
18 18 
19 16 
20 22 
21 32 
22 27 
23 28 
24 25 
25 25 
26 20 
27 25 
28 23 
29 25 
30 23 
31 20 
32 20 
33 21 
34 33 
35 24 
36 24 
37 32 
38 24 
39 25 
40 22 
Totals 1 40 24.3 (0.4) 
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Table 32. C57BR/cdj (89 hours post hCG) 
Cell number/ 
No. expts. Observation No. embryo 
1 13 
2 16 
3 14 
4 17 
5 10 
6 16 
7 13 
8 11 
9 9 
10 16 
11 28 
12 22 
13 17 
14 18 
15 18 
16 20 
17 20 
18 30 
19 15 
20 18 
21 30 
22 26 
23 27 
24 28 
25 25 
26 14 
27 21 
28 23 
29 23 
30 23 
31 16 
32 27 
33 10 
34 10 
35 10 
36 12 
37 20 
38 32 
39 20 
40 20 
41 20 
42 26 
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Table 32. Continued 
Cell number/ 
No. expts. Observation No, embryo 
43 25 
44 24 
45 17 
46 17 
47 21 
48 9 
49 23 
50 16 
51 12 
52 16 
53 16 
54 12 
55 16 
Totals 2 55 18.7 (1.0) 
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Table 33. C3H.B10 (65 hours post hCG) 
Cell number/ 
No. expts. Observation No. embryo 
1 7 
2 9 
3 8 
4 8 
5 8 
6 8 
7 7 
8 7 
9 7 
10 6 
11 8 
12 8 
13 9 
14 8 
15 8 
16 8 
17 7 
18 8 
19 8 
20 8 
21 8 
22 8 
23 7 
24 7 
25 6 
26 8 
27 8 
28 8 
29 4 
30 8 
31 8 
32 8 
33 5 
Totals 1 33 7.6 (0.2) 
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Table 34. C3H.B10 (89 hours post hCG) 
Cell number/ 
No. expts. Observation No. embryo 
0 0 
1 34 
2 32 
3 30 
4 30 
5 31 
6 29 
7 30 
8 31 
9 26 
10 32 
11 34 
12 32 
13 32 
14 33 
15 32 
16 20 
17 32 
18 34 
19 33 
20 33 
21 32 
22 32 
23 32 
24 26 
25 30 
26 37 
27 32 
28 32 
29 27 
30 37 
31 32 
32 30 
33 34 
34 34 
35 33 
Totals 3 35 31.5 (0.6) 
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Table 35. Cross 1 (65 hours post hCG) 
Cell number/ 
No. expts. Observation No. embryo 
1 4 
2 4 
3 8 
4 9 
5 6 
6 7 
7 6 
8 6 
9 6 
10 7 
11 7 
12 8 
13 5 
14 5 
15 5 
16 . 6 
17 7 
18 8 
19 8 
20 8 
21 8 
22 8 
23 8 
24 8 
25 7 
26 7 
27 5 
28 6 
29 8 
30 8 
31 8 
32 8 
33 8 
34 7 
35 8 
36 8 
37 7 
38 8 
39 9 
40 8 
41 6 
42 6 
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Table 35. Continued 
Cell number/ 
No. expts. Observation No. embryo 
43 7 
44 8 
45 8 
46 8 
Totals 2 46 7.1 (0.3) 
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Table 36. Cross 2 (65 hours post hCG) 
Cell number/ 
No. expts. Observation No. embryo 
1 4 
2 7 
3 7 
4 4 
5 7 
6 6 
7 6 
8 7 
9 7 
10 7 
11 7 
12 8 
13 6 
14 6 
15 6 
16 8 
17 8 
18 8 
19 7 
20 6 
21 5 
22 8 
23 8 
24 8 
25 8 
26 8 
27 7 
28 8 
29 6 
30 7 
31 6 
32 7 
33 7 
34 7 
35 5 
36 5 
37 7 
38 7 
39 7 
Totals 1 39 6.8 (0.3) 
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Table 37. Cross 1 
Cell number/ 
No. expts. Observation No. embryo 
1 21 
2 14 
3 31 
4 16 
5 26 
6 26 
7 18 
8 18 
9 20 
10 20 
11 16 
12 21 
13 20 
14 34 
15 16 
16 32 
17 16 
18 22 
19 33 
20 19 
21 14 
22 31 
23 34 
24 14 
25 21 
26 22 
27 18 
28 16 
29 29 
30 20 
31 32 
32 32 
33 26 
34 27 
35 26 
36 29 
37 26 
38 56 
39 31 
40 32 
41 16 
42 28 
43 12 
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Table 37. Continued 
Cell number/ 
No. expts. Observation No. embryo 
44 
45 
46 
47 
48 
32 
18 
26 
16 
34 
Totals 1 48 24.2 (1.4) 
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Table 38. Cross 2 
Cell number/ 
No. expts. Observation No. embryo 
1 29 
2 16 
3 16 
4 32 
5 21 
6 16 
7 16 
8 15 
9 32 
10 29 
11 10 
12 24 
13 24 
14 32 
15 10 
16 16 
17 24 
18 24 
19 32 
20 32 
21 28 
22 30 
23 18 
24 24 
25 32 
26 37 
27 14 
28 20 
29 18 
30 24 
31 24 
32 24 
33 12 
34 18 
35 18 
36 64 
37 29 
38 14 
39 28 
Totals 1 39 24.4 (1.5) 
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Table 39. Cross 3 
Cell number/ 
No. expts. Observation No. embryo 
1 12 
2 24 
3 24 
4 14 
5 14 
6 24 
7 26 
8 32 
9 32 
10 10 
11 12 
12 10 
13 32 
14 26 
15 20 
0 0 
16 20 
17 23 
18 16 
19 26 
20 16 
21 26 
22 16 
23 34 
24 27 
25 27 
26 12 
27 16 
28 16 
29 16 
30 27 
31 27 
32 28 
33 21 
34 22 
35 28 
36 29 
37 22 
38 22 
39 30 
40 32 
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Table 39. Continued 
Cell number/ 
No. expts. Observation No. embryo 
41 52 
42 32 
43 48 
44 46 
45 36 
46 43 
47 42 
48 36 
49 32 
50 34 
51 34 
52 32 
53 46 
Totals 3 53 26.4 (1.5) 
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Table 40. Cross 4 
Cell number 
No. expts. Observation No. embryo 
1 1 10 
2 12 
3 10 
4 32 
5 28 
6 18 
7 32 
8 16 
9 32 
10 16 
11 16 
12 23 
13 26 
14 27 
15 26 
16 27 
17 36 
18 28 
19 26 
20 27 
21 43 
22 26 
23 43 
24 43 
25 46 
26 29 
27 29 
2 0 0 
3 28 38 
29 32 
30 29 
31 32 
32 12 
33 20 
34 12 
35 21 
36 14 
37 18 
38 18 
39 16 
40 26 
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Table 40. Continued 
Cell number 
No. expts. Observation No. embryo 
41 
42 
43 
44 
45 
14 
18 
16 
20 
35 
Totals 3 45 24.8 (1.4) 
Table 41. Backcross 1. ^iXPi 
Cell number 
No. expts. Observation No. embryo 
1 22 
2 24 
3 24 
4 52 
5 28 
6 25 
7 36 
8 34 
9 32 
10 32 
11 32 
12 26 
13 44 
14 32 
15 47 
16 43 
17 44 
18 42 
19 34 
20 37 
21 32 
22 39 
23 32 
24 32 
25 28 
26 23 
27 27 
28 28 
29 24 
30 25 
31 29 
32 29 
33 28 
Totals 3 33 32.3 (1.4) 
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Table 42. Backcross 2. F]^XP2 
Cell number 
No. expts. Observation No, embryo 
1 20 
2 20 
3 14 
4 10 
5 16 
6 26 
7 23 
8 23 
9 27 
10 20 
11 14 
12 14 
13 24 
14 24 
15 21 
16 21 
17 16 
18 16 
19 16 
20 30 
21 22 
22 12 
23 16 
24 29 
25 21 
26 24 
27 12 
28 29 
29 16 
30 16 
31 16 
32 20 
33 21 
34 12 
Totals 1 34 19.6 (0.9) 
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Table 43. B10D2 (65 hours post hCG) 
Cell number/ 
No. expts. Observation No. embryo 
1 3 
2 4 
3 4 
4 12 
5 8 
6 8 
7 8 
8 11 
9 8 
10 5 
11 8 
12 8 
13 8 
14 6 
15 9 
16 8 
17 8 
18 7 
19 6 
20 8 
21 8 
22 8 
23 8 
24 5 
25 5 
26 7 
27 8 
28 7 
29 7 
30 7 
31 8 
32 8 
33 2 
34 8 
35 2 
36 2 
37 8 
38 4 
39 7 
40 3 
41 6 
42 3 
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Table 43. Continued 
Cell number/ 
No. expts. Observation No. embryo 
43 3 
44 8 
45 8 
46 7 
47 7 
Totals 2 47 6.5 (0.3) 
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Table 44. BIO.Q (65 hours post hCG) 
Cell number 
No. expts. Observation No. embryo 
1 8 
2 8 
3 7 
4 8 
5 8 
6 8 
7 8 
8 8 
9 7 
10 6 
11 7 
12 8 
13 8 
14 8 
15 8 
16 7 
17 7 
18 6 
19 8 
20 4 
21 7 
22 8 
23 7 
24 4 
25 8 
26 8 
27 8 
28 7 
29 7 
30 8 
31 8 
32 8 
33 8 
34 8 
35 8 
36 8 
37 7 
Totals 1 37 7.4 (0.2) 
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Table 45. BIO.RIII (65 hours post hCG) 
Cell number/ 
No. expts. Observation No. embryo 
1 5 
2 6 
3 8 
4 2 
5 4 
6 2 
7 2 
8 3 
9 5 
10 5 
11 5 
12 7 
13 7 
14 6 
15 8 
16 8 
17 8 
18 6 
19 6 
20 6 
21 8 
22 4 
23 4 
24 4 
25 5 
26 5 
27 5 
28 5 
29 6 
30 8 
31 8 
32 8 
33 8 
34 7 
35 8 
36 7 
37 4 
38 6 
39 8 
Totals 2 39 5.6 (0.4) 
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Table 46. BIO.PL (65 hours post hCG) 
Cell number/ 
No. expts. Observation No. embryo 
0 0 
1 7 
2 8 
3 8 
4 5 
5 6 
6 8 
7 8 
8 8 
9 7 
10 2 
11 8 
12 8 
13 5 
14 6 
15 8 
16 8 
17 8 
18 8 
Totals 2 18 7.0 (0.6) 
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Table 47. B10.D2 (89 hours post hCG) 
Cell number 
No. expts. Observation No. embryo 
1 45 
2 40 
3 32 
4 46 
5 54 
6 32 
7 45 
8 50 
9 26 
10 42 
11 34 
12 56 
13 52 
14 32 
15 32 
16 44 
17 44 
18 46 
19 39 
20 32 
21 32 
22 41 
23 40 
24 48 
25 43 
26 25 
27 41 
28 42 
29 63 
30 42 
31 39 
32 21 
33 46 
34 32 
35 62 
36 54 
37 22 
38 48 
39 28 
40 32 
41 32 
42 32 
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Table 47. Continued 
Cell number 
No. expts. Observation No. embryo 
43 24 
44 26 
45 46 
46 32 
47 32 
Totals 2 47 39.1 (1.5) 
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Table 48. BIO.Q (89 hours post hCG) 
Cell number 
No. expts. Observation No. embryo 
1 38 
2 32 
3 32 
4 32 
5 32 
6 32 
7 22 
8 21 
9 38 
10 29 
11 22 
12 38 
13 20 
14 37 
15 31 
16 32 
17 41 
18 29 
19 35 
20 35 
21 31 
22 32 
23 26 
24 36 
25 26 
26 31 
27 18 
28 45 
29 22 
30 16 
31 27 
32 37 
33 16 
34 32 
Totals 2 34 30.2 (1.3) 
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Table 49. BIO.RIII (89 hours post hCG) 
Cell number 
No. expts. Observation No. embryo 
1 14 
2 24 
3 38 
4 32 
5 26 
6 24 
7 24 
8 28 
9 34 
10 22 
11 10 
12 21 
13 22 
14 25 
15 27 
16 30 
17 23 
18 32 
19 28 
20 32 
21 14 
22 30 
23 25 
24 26 
25 28 
26 38 
27 25 
28 24 
29 16 
30 17 
31 34 
32 28 
33 22 
34 24 
35 26 
36 27 
37 14 
38 30 
39 36 
40 27 
41 21 
42 34 
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Table 49. Continued 
Cell number 
No. expts. Observation No. embryo 
43 
44 
45 
46 
18 
22 
26 
26 
Totals 2 46 25.4 (0.9) 
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Table 50. BIO.PL (89 hours post hCG) 
Cell number/ 
No. expts. Observation No. embryo 
0 0 
1 54 
2 28 
3 10 
4 40 
5 28 
6 28 
7 41 
8 14 
9 50 
10 28 
11 50 
12 32 
13 14 
14 23 
15 26 
16 44 
17 18 
18 20 
19 21 
20 20 
21 19 
22 34 
23 28 
24 32 
25 36 
26 38 
27 30 
28 32 
29 32 
30 32 
31 32 
32 33 
33 30 
34 32 
35 30 
Totals 3 35 30.4 (1.7) 
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Table 51. BALB/c (65 hours post hCG) 
Cell number/ 
No. expts. Observation No. embryo 
1 8 
2 5 
3 4 
4 4 
5 4 
6 4 
7 7 
8 4 
9 4 
10 4 
11 4 
12 4 
13 4 
14 4 
15 4 
16 4 
17 4 
18 4 
19 4 
20 4 
21 3 
22 3 
23 3 
24 3 
25 4 
26 4 
27 4 
28 4 
29 4 
30 4 
31 4 
32 3 
33 4 
34 4 
35 3 
36 2 
37 6 
38 7 
39 6 
40 8 
41 8 
42 8 
43 5 
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Table 51. Continued 
Cell number 
No. expts. Observation No. embryo 
44 5 
45 4 
46 4 
47 4 
48 6 
49 2 
50 3 
Totals 3 50 4.5 (0.2) 
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Table 52. BALB.B (65 hours post hCG) 
Cell number 
No. expts. Observation No. embryo 
1 2 
2 3 
3 2 
4 3 
5 3 
6 2 
7 2 
8 3 
9 2 
10 3 
11 3 
12 3 
13 3 
14 3 
15 3 
16 3 
17 6 
18 4 
19 6 
20 4 
21 4 
22 4 
23 4 
24 7 
25 4 
26 4 
27 4 
28 4 
29 4 
30 7 
31 4 
32 7 
33 4 
34 4 
35 4 
36 4 
37 4 
38 4 
39 4 
40 4 
41 4 
42 7 
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Table 52. Continued 
Cell number 
No. expts. Observation No. embryo 
43 6 
44 6 
45 8 
46 9 
Totals 1 46 4.1 (0.1) 
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Table 53. BALB.K (65 hours post hCG) 
Cell number/ 
No. expts. Observation No. embryo 
1 4 
2 4 
3 4 
4 4 
5 4 
6 4 
7 4 
8 4 
9 4 
10 4 
11 3 
12 3 
13 8 
14 8 
15 4 
16 4 
17 4 
18 4 
19 4 
20 4 
21 4 
22 4 
23 4 
24 4 
25 4 
26 4 
27 3 
28 3 
29 3 
30 3 
31 7 
32 7 
33 7 
34 4 
35 4 
36 3 
37 3 
38 4 
39 4 
40 8 
41 8 
42 3 
43 4 
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Table 53. Continued 
Cell number/ 
No. expts. Observation No. embryo 
44 3 
45 8 
46 4 
47 4 
48 4 
49 4 
50 4 
51 3 
52 7 
53 3 
54 7 
55 3 
56 3 
47 3 
58 3 
59 6 
60 6 
61 5 
62 3 
63 3 
64 3 
65 5 
Totals 1 65 4.3 (0.03) 
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Table 54. BALB/c (89 hours post hCG) 
Cell number/ 
No. expts. Observation No. embryo 
1 28 
2 18 
3 34 
4 18 
5 42 
6 31 
7 24 
8 18 
9 29 
10 9 
11 31 
12 25 
13 27 
14 25 
15 30 
16 23 
17 21 
18 15 
19 13 
20 26 
21 40 
22 27 
23 16 
24 15 
25 29 
26 9 
27 39 
28 11 
29 22 
30 15 
31 17 
32 34 
33 15 
34 28 
35 44 
36 9 
37 15 
38 21 
39 21 
40 17 
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Table 54. Continued 
Cell number/ 
No. expts. Observation No. embryo 
41 29 
42 22 
43 22 
44 10 
45 11 
46 29 
47 28 
48 23 
49 9 
Totals 4 49 22.0 (1.4) 
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Table 55. BALB.B (89 hours post hCG) 
Cell number/ 
No. expts. Observation No. embryo 
1 28 
2 15 
3 22 
4 34 
5 23 
6 24 
7 14 
8 22 
9 24 
10 36 
11 19 
12 16 
13 32 
14 30 
15 30 
16 18 
17 8 
18 21 
19 21 
20 24 
21 24 
22 20 
23 18 
24 32 
25 28 
25 27 
27 38 
28 11 
29 9 
30 17 
31 42 
32 23 
Totals 1 32 23.1 (2.8) 
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Table 56. BALB.K (89 hours post hCG) 
Cell number 
No. expts. Observation No. embryo 
1 16 
2 17 
3 28 
4 14 
5 28 
6 27 
7 20 
8 14 
9 30 
10 28 
11 26 
12 21 
13 20 
14 19 
15 16 
16 10 
17 10 
18 11 
19 19 
20 23 
21 22 
22 22 
23 21 
24 14 
25 10 
26 21 
27 28 
28 18 
29 12 
30 30 
31 8 
32 16 
33 14 
34 14 
35 13 
36 30 
37 23 
38 17 
39 12 
40 21 
41 9 
42 10 
43 19 
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Table 56. Continued 
Cell number 
No. expts. Observation No. embryo 
44 21 
45 14 
46 23 
47 23 
48 7 
49 12 
50 29 
51 26 
52 16 
53 20 
54 21 
55 26 
56 14 
57 14 
58 9 
59 26 
60 20 
61 19 
62 22 
63 15 
64 28 
65 13 
Totals 1 65 18.1 (0.8) 
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Table 57. CBAg, x BALB/cd* (65 hours post hCG) 
Cell number 
No. expts. Observation No. embryo 
1 3 
2 3 
3 3 
4 4 
5 4 
6 4 
7 4 
8 4 
9 2 
10 2 
11 3 
12 3 
13 3 
14 4 
15 4 
16 4 
17 4 
18 4 
19 5 
20 6 
21 3 
22 3 
23 4 
24 3 
25 3 
26 4 
27 4 
28 4 
29 2 
30 4 
31 3 
32 3 
33 3 
34 4 
35 5 
36 4 
37 4 
38 4 
39 3 
Totals 2 39 3.6 (0.1) 
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Table 58. BALB/cç x CBAd* (65 hours post hCG) 
Cell number/ 
No. expts. Observation No. embryo 
1 4 
2 4 
3 7 
4 4 
5 4 
6 4 
7 4 
8 4 
9 8 
10 7 
11 4 
12 6 
13 4 
14 4 
15 3 
16 6 
17 5 
18 6 
19 7 
20 5 
21 3 
22 3 
23 3 
24 2 
25 4 
26 7 
27 8 
28 6 
29 5 
30 4 
Totals 1 30 4.9 (0.1) 
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Table 59. BALB/cç x CBAcf* (89 hours post hCG) 
Cell number/ 
No. expts. Observation No. embryo 
1 19 
2 19 
3 27 
4 15 
5 31 
6 30 
7 13 
8 26 
9 4 
10 25 
11 26 
12 28 
13 18 
14 16 
15 20 
16 20 
17 21 
18 23 
19 21 
20 19 
21 20 
22 19 
23 22 
24 24 
25 24 
26 26 
27 26 
28 25 
29 28 
30 8 
31 40 
32 15 
33 27 
34 26 
35 26 
36 42 
37 26 
38 32 
39 18 
40 16 
41 14 
42 24 
201 
Table 59. Continued 
Cell number 
No. expts. Observation No. embryo 
43 
44 
45 
46 
47 
22 
22 
28 
24 
23 
Totals 2 47 23.5 (0.9) 
202 
Table 60. CBAç x BALB/c<? (89 hours post hCG) 
Cell number/ 
No. expts. Observation No. embryo 
1 13 
2 12 
3 15 
4 12 
5 13 
6 12 
7 15 
8 15 
9 17 
10 30 
11 21 
12 21 
13 16 
14 10 
15 15 
16 16 
17 15 
18 15 
19 28 
20 16 
21 22 
22 22 
23 16 
24 18 
25 28 
26 16 
27 28 
28 32 
Totals 3 28 18.3 + 1.2 
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VIII. APPENDIX B. 
RAW DATA FOR LABELING OF EMBRYOS 
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Table 61. Raw data for Table 20 
Expt. 
No. 
Control 
cpm 
Control 
cpm/embryo 
Experimental 
cpm 
Experimental 
cpm/ embryo Ratio a 
Dilution 1:20 
Clone 11-4.1. A/J embryos 
1 
2 
3 
4 
476 
476 
432 
432 
119 
119 
108 
108 
405 
501 
400 
474 
101 
125 
100 
119 
0.85 
1.05 
0.93 
1.10 
Dilution 1:50 
1 
2 
3 
4 
393 
393 
393 
393 
98 
98 
98 
98 
303 
360 
376 
196 
76 
90 
94 
50 
0.78 
0.92 
0.96 
0.52 
Dilution 1:100 
560 
560 
140 
140 
615 
609 
154 
152 
09 
08 
aRat-io = Expt. cpm/embryo 
Ayg. control cpm/embryo * 
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Table 62. Raw data for Table 20 
Expt. Control Control Experimental Experimental ^ 
No. cpm cpm/embryo cpm cpm/embryo Ratio 
Clone 9A2-D2. A/J embryos 
Dilution 1:20 
1 287 144 240 120 0.84 
2 287 144 243 122 0.85 
3 81 81 106 106 1.3 
Dilution 1:50 
1 400 100 454 113 1.13 
2 400 100 550 137 1.37 
Clone 10E3-C12. A/J embryos 
Dilution 1:20 
1 420 140 390 130 0.93 
2 420 135 374 125 0.92 
Dilution 1:50 
1 133 133 185 185 1.39 
2 133 133 186 186 1.39 
Dilution 1:100 
1 186 93 214 107 1.15 
aRatio _ Expt. cpm/embryo 
Avg. control cpm/embryo ' 
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Table 63. Raw data for Table 21 (dilution 1:20) 
Expt. Control Control Experimental Experimental ^ 
No. cpm cpm/embryo cpm cpm/embryo Ratio 
CBA embryos 
Clone 11-4.1 
1 653 218 359 120 0.55 
2 653 218 391 130 0.59 
3 747 250 406 135 0.54 
4 747 250 280 93 0.37 
5 747 250 467 155 0.02 
6 747 250 309 103 0.41 
Clone 9A2-D2 
1 185 93 206 103 1.1 
2 185 93 250 125 1.3 
3 218 109 184 93 0.86 
4 218 109 274 137 1.25 
Clone 5D2B10 
1 150 75 100 50 0.66 
2 150 75 108 54 0.72 
3 142 142 122 122 0.86 
= Sxpt. cpm/embryo 
Ayg. control cpm/embryo ' 
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Table 64. Raw data for Table 21 (1:20 dilution) 
Exp t. Control Control Experimental Experimental 
No. cpm cpm/embryo cpm cpm/embryo Ratio 
Clone 11-4.1 
C57BR/cdi embryos 
1 
2 
464 
464 
151 
151 
362 
623 
121 
207 
0.82 
1.37 
Clone 9A2D2 
1 
2 
160 
160 
80 
80 
102 
208 
51 
104 
0.65 
1.3 
Clone D52-B10 
1 123 
2 123 
3 176 
123 
123 
88 
114 
129 
169 
114 
129 
84 
0.93 
1.05 
0.95 
Clone 10E3-C12 
1 
2 
566 
283 
141 
142 
301 
90 
76 
45 
0.54 
0.32 
Ratio = Exp t. cpm/ embryo 
Avg. control cpm/entryo' 
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Table 65. Raw data for Table 21 (1:20 dilution) 
Expt. Control Control Experimental Experimental 
No. cpm cpm/embryo cpm cpm/embryo Ratio 
C57BL/6 embryos 
Clone 2H1-5B 
1 109 55 170 85 1.54 
2 142 71 162 81 1.14 
3 142 71 134 67 0.82 
4 142 71 258 129 1.80 
5 119 119 107 107 0.9 
6 119 119 134 134 1.13 
7 119 119 106 106 0.89 
Exp t. cpm/embryo 
Avg. control cpm/embryo * 
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IX. APPENDIX C. 
CELL FUSION PROTOCOL IN SUMMARY 
Procedure 
Prepare HAT medium by mixing 100 ml 
of complete medium with 1.2 ml HAT 
Prepare PEG by adding 2.7 ml PBS to 
2.25 gm PEG-1540 and warming in a 
37°C water bath 
Count cells by adding 0.1 ml of the 
diluent to 0.4 ml of cell suspension 
in a tube 
Prepare Sp-2/0 or NS-1 cell suspen­
sion by combining the necessary cells 
in a 50 ml centrifuge tube 
Kill immunized mice and harvest 
spleen. Soak the mouse in 70% ETOH. 
Cut away skin and muscle over left 
flank. Use new instruments to take 
out the spleen with a minimum of 
attached fat. Place spleen in petri 
dish. 
Extract spleen cells. Inject 2 ml 
of D-MEM (serum free) into spleen. 
Set spleen screen over petri dish. 
Scratch gently the spleen pulp 
against the screen using sterile 
forceps. Rinse through screen with 
1 ml D-MEM (serum free). Remove 
cell suspension from petri dish and 
place in a sterile tube. 
Count spleen cells using a sterile 
red cell pipet. A 1:100 dilution is 
made using white blood cell diluting 
fluid. Calculate cell mixture. The 
desired ratio of myeloma to spleen 
cells is 1:5. Wash myeloma cells 
and resuspend them in 10 ml of D-MEM 
serum free. 
Supplies 
HAT stock solutions, 
complete medium. 
PBS, PEG, 5 ml pipet, 
37° water bath 
Disposable tubes, trypan 
blue, 1 ml sterile pipettes, 
hematocytometer 
50 ml centrifuge tube 
70% ETOH, 1 cc tubercu-
line syringe, 2 sterile 
forceps (smooth edged), 
2 sterile scissors, 1 60 mm 
plastic petri dish, 1 5 ml 
sterile pipet 
1 5 stainless steel mash 
screen, 1 pair disposable 
gloves, 1 sterile forceps; 
1 ice tuberculin syringe, 
1 sterile tube 
Sterile red cell pipettes, 
white blood cell diluting 
fluid 
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Procedure 
8. Mix both cell populations and centri­
fuge the mixture at 200xg for 8 
minutes (room temperature). 
9. Remove supernatant from cell mix­
ture by absorbing with sterile 
pasteur pipettes connected to a 
vacuum. 
10. Disperse pellet by flicking the 
tip of the tube. 
11. Once the PEG is dissolved, filter 
sterilize in place in a sterile 
tube. 
12. Total time 45 seconds; slowly add 
0.5-1 ml of PEG. Gently mix by 
swirling the tube. 
13. Place tube in 37°C for 45 seconds. 
14. Total time 1 minute. Add 1 ml of 
D-MEM (serum free) without dis­
turbing the clumps. Rotate the 
tube gently in the process. 
15. Total time 3 minutes. Gently add 
10 ml of D-MEM (serum free) with­
out disturbing the clumps. Care­
fully mix by inverting the tube. 
16. Centrifuge at 225xg for 8 minutes 
(room temperature). 
17. Dilute cells to the equivalent of 
5 X 10^~ myeloma cells/ml by 
adding 1 ml of complete medium and 
dispersing the pellet gently with a 
sawed off pipet. Add the remaining 
medium. Take one-third of the total 
volume of this cell suspension and 
make a final dilution of 2.5 x 10^ 
myeloma cells/ml using complete 
medium. Mix slowly. 
Supplies 
Centrifuge 
Sterile pasteur pipettes, 
trap system vacuum 
PEG solution, 3 ml syringe, 
0.22 pm filter 
1 sawed off sterile pipet, 
timer 
37°C water bath 
1 ml sterile pipet, D-MEM 
(serum free). 
1 10 ml sterile pipet, 
D-MEM (serum free) 
Centrifuge 
Complete medium (D-MEM + 
serum), sawed off pipettes 
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Procedure Supplies 
18. Dispense both cell suspensions in 96 well plates, sawed off 
separate plates by delivering 0.2 pipettes 
ml of the suspension in each well 
using a sawed off pipet. 
19. Incubate at 37°C, 5% CO2, high 
humidity. 
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X. APBEKDIX D. 
QUANTITATIVE GEMETICS INTERPRETATION 
After consulting with one of the members of my committee, I decided 
that a quantitative genetics interpretation of my results was needed, 
and, therefore, included in this appendix. 
From our thesis and from previous work, we know the following facts: 
1. The H-2 antigens show Mendelian segregation 
2. The Ped effect is clearly a quantitative trait. 
Quantitative traits are determined by major gene effects, poly­
genic effects, gene environment interactions and environment effects. 
Thus, the variance of the Ped effects can be summarized as follows: 
Variance of Ped effects = 0^ major genes + polygenes (background) + 
2 CT environment effects. 
A polygene is defined as a gene with a small effect. In general, 
a quantitative trait is determined by many polygenes and sometimes by 
a few major genes (i.e., genes with relative large effects). Experi­
mentally, single polygenic effects are usually not isolated, while major 
gene effects may be. In Table 66, we present data reestablishing the 
quantitative genetic facts of our experiments. 
An estimation of the number of Ped loci would be (from Hartl, 1980): 
_2 
8(.ah^ - A^F^) 
= 3.5 
D = numerical difference between the two parental means. 
The equation - o^F^ = 3.9 is an estimate of the genetic 
variance in the F^ population. An estimate of the fraction of variance 
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Table 66. Variances of P^, P^, F^, F^ and backcross generations 
Generation 
Mean cell No./ 
embryo C7 *2 
^1 
33.1 14.5 211.6 
^2 
22.6 8.9 79.3 
Fl 29.5 9.2 84.6 
^2 
25.0 9.41 88.5 
Backcross^ (PgXF^^) 19.6 5.2 27.6 
Backcross2 (P^XF^) 32.3 8.0 64.7 
3 9 in the population which is genetic is gg'^ = 0.04. Thus, only 4% 
of the variation in the population is genetic. This is typical of 
quantitative traits. From these data and other evidence presented, we 
can construct the following two hypotheses: 
I. The H-2 k and b haplotypes show pleiotropy and the Ped ef­
fects are determined by genes at the H-2 complex. 
II. Linked to H-2 (k and b haplotypes) is one or more Ped genes 
uniquely responsible for the observed Ped effect. 
We can conclude that if the Ped effect is uniquely linked to H-2 
and H-2^ haplotypes, we should expect a mendelian distribution such as 
the model presented in Table 9. From the experimental data presented, 
mendelian segregation is not evident. Thus, the most feasible interpreta­
tion compatible with our results is that the Ped effect is associated 
If 
with a quantitative trait, some genes of which are linked to the H-2 
and H-2^ haplotypes. In addition, the background gene effects which 
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are discussed (see Table 12) are interpreted as non-H-2 polygenic 
effects. 
